RESEARCH ARTICLE

Open Access



Hyun-Tae Shin^{1,2†}, Byung Woo Yoon^{3†} and Je Hyun Seo^{1*} ^(D)

Abstract

Background: The prevalence of open-angle glaucoma (OAG) varies from 0.5% to 7.0% among populations of diverse ancestry, suggesting the existence of genetic differences. The purposes of this study were to provide insights into genetic causes of OAG, which can result in prevalence and phenotype differences among populations of diverse ancestry for OAG, and to compare allele frequencies of intraocular pressure (IOP) elevation-related SNPs in OAG among Koreans and other ethnic groups.

Methods: We collected the data on a total of 135 OAG-associated single nucleotide polymorphisms (SNPs) from a genome-wide association studies (GWAS) catalog. The population-level allele frequencies of these SNPs were derived based on the 1000 Genomes Project and Korean Reference Genome Database. We used Fisher's exact test to assess whether the effect allele at a given SNP was significantly enriched or depleted.

Results: European, American, and South Asian populations showed similar heatmap patterns, while African, East Asian, and Korean populations had distinct patterns. Korean population presented different profiles compared to other groups; rs1579050 (*FMNL2* gene), rs2024211 (*CAV2;CAV1*), and rs8141433 (*GNB1L;TXNRD2* gene), which are known to be associated with IOP variation, were enriched in Americans, Europeans, and Africans, and depleted in Koreans. These can be the candidates for the causative genes of differences in the prevalence of IOP variation in OAG according to ethnic groups.

Conclusions: Differences in allele frequencies associated with IOP related SNPs between Koreans and other ethnicities were observed, which may explain the high prevalence of OAG with normal IOP predominantly in Koreans and East Asians.

Keywords: Open-angle glaucoma, Allele frequency, Single nucleotide polymorphism, Intraocular pressure, Prevalence, Normal-tension glaucoma

Background

Glaucoma, which is a progressive optic neuropathy characterized by degeneration of the retinal ganglion cells and their axons and a corresponding visual field defect [1], is a leading cause of irreversible blindness worldwide. Prevalence of glaucoma varies among ethnicity and regions, from 0.5% to 8.0% for open-angle glaucoma (OAG) [2–5],

*Correspondence: jazmin2@naver.com

[†]Hyun-Tae Shin and Byung Woo Yoon contributed equally to this work ¹ Veterans Health Service Medical Center, Veterans Medical Research Institute, Jinhwangdo-ro 61-gil 53,Gangdong-gu, Seoul 05368, Korea Full list of author information is available at the end of the article



© The Author(s) 2021. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

and from 0.1% to 2.3% for angle-closure glaucoma [6–8], suggesting the existence of genetic differences among populations of diverse ancestry. As OAG is the predominant form of glaucoma, epidemiologic research regarding diverse ancestry populations has been conducted [2, 5, 9-12]. According to a meta-analysis report [13], the prevalence of OAG was higher in Africans, followed by Europeans and Asians. Still, there were little data on other ethnic groups, such as South and East Asians. A recent study complementing this has shown that the prevalence of OAG was higher in Africans and Latinos, followed by Europeans, South Asians, and East Asians [14]. The relationship between the prevalence and geographical variations might encompass genetic, environmental, and cultural differences.

Evidence for a causal relationship between elevated intraocular pressure (IOP) and OAG is robust, but normal-tension glaucoma (NTG) is considered a part of the spectrum of OAG intrinsically, which is arbitrarily based on the distribution of IOP; OAG with IOP \leq 21 mmHg is termed as NTG. Specifically, NTG is common in Asians, including Koreans (77.0%) and comprises the majority (52-92%) of cases of OAG in Asian studies [15-18]; the proportions are higher than those in Europeans (30-38%)and African ancestry populations (57.1%) [3, 19, 20]. This difference in the pattern of prevalence of NTG according to populations of diverse ancestry suggested that it may be related to different allele frequencies of glaucoma-related single nucleotide polymorphism (SNP). In addition, first-degree relatives of affected patients are estimated to have as much as 4 to 10 times increased risk compared to the general population [21, 22]. These suggest that genetic aspects should be considered as a cause of glaucoma. Recently, studies based on genomewide association study (GWAS) of glaucoma with metaanalysis using the results from various cohorts such as International Glaucoma Genetics Consortium (IGGC), Australian and New Zealand Registry of Advanced Glaucoma (ANZRAG), and UK Biobank (UKBB) had revealed novel risk loci and SNPs related with IOP [23-26]. Combining these results using the GWAS catalog (NHGRI-EBI) [27] and utilizing 1000 Genomes Project phase 3 data [28], we could infer the difference in glaucoma-related SNPs according to populations of diverse ancestry. Additionally, it is possible to assess the allele frequency of OAG-associated SNPs and IOP elevationassociated SNPs in OAG among Koreans using 1722 whole-genome sequencing data of healthy Koreans in the Korean Reference Genome Database (KRGDB) [29].

Hence, the purposes of this study were to gain insights into genetic causes of OAG, which can result in prevalence and phenotype differences among populations of diverse ancestry for OAG, and to compare allele frequencies of IOP elevation-related SNPs in OAG among Koreans and other population groups. We also developed the composite genetic risk score for OAG as a whole and OAG with high IOP and tested the correlation between a population-level average of composite risk scores and OAG prevalence.

Methods

This study was approved and monitored by the Institutional Review Board (IRB) of the Veterans Health Service Medical Center, Korea (IRB No. 2019-07-008).

Comparison of OAG-related SNPs in global population and East Asians

According to the International Society of Geographical and Epidemiological Ophthalmology (ISGEO) classification [30], OAG is defined as glaucomatous optic neuropathy in the presence of an open angle and no other ocular abnormality accountable for the neuropathy. We researched the GWAS catalog (NHGRI-EBI, https:// www.ebi.ac.uk/gwas/docs/file-downloads, "All associations v1.0.2—with added ontology annotations, GWAS Catalog study accession numbers and genotyping technology", December 2019) for SNPs that were associated with 'open-angle glaucoma'-related trait (EFO_0004190). Initially, 146 glaucoma-associated SNPs from the GWAS catalog were collected. Of these, a total of 135 SNPs was used for analysis after removing the repeated ones (Additional files 2, 3: Table S1 and Table S2).

Among SNPs associated with OAG-related trait, we determined OAG risk by examining the sign of betacoefficient, whether the odds ratio for the effect allele was greater than one, and text description in the primary GWAS reports. The details and advantages of the method have been described elsewhere [31]. In brief, the population-level allele frequencies of these SNPs were derived based on the 1000 Genomes Project phase 3 (n=2504)and KRGDB (n = 1722). The 1000 Genomes Project surveys genetic variations among 2504 individuals from 26 worldwide populations, which can be grouped into African (AFR), East Asian (EAS), European (EUR), South Asian (SAS), and the American (AMR) based on their geographical locations and ancestries [28]; the data were downloaded from ftp://ftp.1000genomes.ebi.ac.uk/vol1/ ftp/release/20130502/ (last accessed: January 15, 2020). Because the East Asian data in the 1000 Genomes Project did not include data from the Korean population, we compared the data from the five continents with data extracted from KRGDB, which included the whole genome sequencing data for 1722 Korean (KOR) individuals [29]. The data on the population frequency of the SNPs were downloaded from the web-based database (http://152.99.75.168:9090/KRGDB/menuPages/downl oad.jsp/, last accessed: January 15, 2020). For the comparison of the distribution of individual risk alleles of the Korean population, individual genotype results of the 2nd phase of KRGDB (n = 1099) were obtained from the National Human Resource Bank of Korea.

Comparison of SNPs related to IOP elevation in OAG in Global population and East Asians

OAG is defined as an optic nerve state, but IOP is considered a major risk factor. Hence, research for allele frequencies of SNPs influencing IOP may give us insights on the difference in the prevalence of NTG and OAG with high IOP according to different ancestries. The 52 SNPs related to IOP are shown in Table 1, which have been obtained from GWAS catalog data, a study using Genetic Epidemiology Research in Adult Health and Aging (GERA) cohort [32], a large multi-ethnic study for identifying novel loci related to IOP [33], and meta-analysis results of IGGC, ANZRAG, and UKBB [23–26]. The population-level allele frequencies of these SNPs were derived as described above.

Composite genetic risk score calculation using SNPs related to OAG and OAG with high IOP

To compare the composite genetic risk of OAG, we adopted the equation suggested by Mao et al. [31] The composite genetic risk score is calculated using the following formula:

Genetic risk score =
$$\frac{\sum_{i=1}^{l} X_i}{2I}$$

where "I" refers to the number of OAG-related SNPs, and "Xi" refers to copies of risk alleles (Xi \in {0,1,2}) at the ith SNP. In one extreme case, if a person has two copies of risk alleles at each OAG-related SNP, then the person's risk score will become 1. On the other hand, if a person has no copy of risk alleles at each OAG-related SNP, then the person's risk score will become 0. A person with a composite score of 1 has the highest possible genetic risk for OAG, while a person with a score of 0 has the lowest possible genetic risk. If copies of effect alleles (0/1/2)are randomly assigned to each SNP, the expected value of the risk score will be 0.5. SNPs with a frequency difference of more than 10% between the total (n = 1722) and the 2nd phase (n = 1099) data of KRGDB were excluded from the genetic score calculation. We used the average of composite genetic risk scores for the populations for correlation with the country-wise OAG prevalence data. In addition, the composite genetic risk score was calculated using IOP elevation-related SNPs for OAG with high IOP. The prevalence of OAG with high IOP was calculated as $(1-\text{the NTG proportion of OAG } [12]) \times \text{the}$ total OAG prevalence. The correlation analysis with the composite genetic risk score and the prevalence of OAG with high IOP was performed.

Data analyses

We used the Kruskal-Wallis rank-sum test to assess OAG related SNP frequencies according to populations of diverse ancestry and Fisher's exact test to assess whether the effect allele at a given SNP is significantly enriched or depleted compared to the global population frequency in the 1000 Genomes Project database, and the P values were first \log_{10} -transformed. In the heatmap generated to visualize allele enrichment or depletion patterns in different populations, red and purple colors meant higher and lower frequencies than the global average, respectively. If the effect allele of an SNP is enriched in a population, then the negative of \log_{10} of the enrichment P-value (a positive number) was used to represent the SNP associated with that population in a heatmap. On the other hand, if the allele of an SNP is depleted in a population, the value of \log_{10} of the depletion *P*-value (a negative number) was used to represent the SNP for that population in the heatmap. Statistical analyses were performed using R software version 3.6.0 (R Foundation, Vienna, Austria). Statistical significance was set at P < 0.05 and $|\log_{10} P| > 1.301$.

Results

Patterns of OAG risk alleles among populations

A total of 135 OAG-related SNPs was obtained from 24 GWAS studies. Among these, 15 studies were performed in Europeans, 13 in East Asians, 4 in South Asians, 7 in Africans, and 2 in Americans (9 studies were performed in mixed ethnic populations). Clearly, populations except Europeans were understudied. However, there was no significant difference in the SNP frequency among these populations with the Kruskal–Wallis ranksum test (Fig. 1). This result suggests that many SNPs found in Europeans are also applicable to other populations. Following collecting the OAG-associated SNPs, we obtained their effect allele frequencies (EAFs) in each of the continental groups and Koreans based on genotype information from the 1000 Genomes Project and KRGDB (Additional file 2: Table 1). A heatmap showed how significantly the effect allele was enriched or depleted across the Korean and continental groups (Additional files 1: Figure S1) with a log scale among 135 OAG-related SNPs. For Koreans, 63 OAG-related SNPs were significantly enriched, 63 SNPs were depleted, and 9 SNPs were similar to global EAF. The heatmap visualized the proportion of effect alleles in each continental group compared to the global average. There were certain patterns of risk allele frequencies depending on continental

č
a a
Æ
$\stackrel{\vee}{\searrow}$
0
Ĕ
ö
⊇
2
. <u> </u>
\geq
st
8
ĕ
σ
Se
Ū.
.≥
0
of
Š
Ē
Ę
σ
Ŋ
дс
ă
S.
E
.s
4
Ē
2
É
$\widehat{}$
ğ
a)
ō
ot
e G
Ū
<u>_</u>
Ē
Ĕ
S.
D.
te
<u>a</u>
Ψ
Ð
Ξ
SS
Le la
0
aľ
К
,a
Jt
. <u>`</u>
of
S)
Ľ,
Ę
) (
ě
<u> </u>
<u>(</u>)
Ľ
0 U
fr
Φ
Ð
all
÷
ĕ
Ë
ч
-
e
ā
Ta
-

Chr	Position	Type	Ref Allele	Alt Allele	Nearby/containing Gene	Global EAF	AMR EAF	AMR log ₁₀ P	AFR EAF	AFR log ₁₀ P	EAS EAF
chr7	117603820	Intergenic	U	U	CTTNBP2;LSM8	0.31	0.28	- 0.735	0.33	0.738	0.1
chr7	116151338	Intergenic	L	U	CAV2;CAV1	0.22	0.21	- 0.177	0.4	36.671	0.0089
chr14	61072875	Intergenic	Г	U	SIX6;SALRNA1	0.35	0.66	51.990	0.034	- 146.666	0.21
chr8	108278616	Intronic	U	A	ANGPT1	0.16	0.18	0.569	0.11	- 5.368	0.23
chr1	165714416	Intronic	Г	U	TMC01	0.92	0.87	- 3.857	0.92	0.000	0.99
chr11	120340383	Intronic	U	A	ARHGEF12	0.21	0.15	- 3.286	0.25	2.601	0.24
chr6	597203	Intronic	U	⊢	EXOC2	0.12	0.11	— 0.249	0.087	- 3.132	0.14
chr3	15005942	Intergenic	U	A	LINC01214;TSC22D2	0.16	0.14	— 0.578	0.16	0.010	0.075
chr9	129373110	Intergenic	U	U	MVB12B;LMX1B	0.23	0.24	0.194	0.11	- 23.178	0.13
chr14	60847001	Intergenic	U	Г	LINC02322;C14orf39	0.63	0.32	- 51.921	0.89	82.782	0.78
chr7	11679113	Intronic	A	5	THSD7A	0.25	0.35	6.518	0.11	- 29.965	0.2
chr2	153364527	Intronic	A	0	FMNL2	0.28	0.46	19.037	0.1	— 46.833	0.026
chr6	51406848	Intergenic	A	0	TFAP2B;PKHD1	0.13	0.13	0.000	0.15	1.166	0.12
chr16	65080739	Intronic	U	A	CDH11	0.2	0.21	0.187	0.085	— 24.499	0.21
chr8	108251139	Intergenic	A	0	ABRA;ANGPT1	0.84	0.83	- 0.204	6.0	7.594	0.77
chr7	116153025	Intergenic	A	U	CAV2;CAV1	0.21	0.2	- 0.177	0.34	20.570	0.0089
chr6	637465	Intronic	U	н	EXOC2	0.11	0.12	0.258	0.045	- 13.535	0.15
chr7	117635382	Intergenic	U	F	CTTNBP2;LSM8	0.33	0.28	- 1.730	0.39	4.233	0.09
chr6	1533116	Intergenic	A	5	FOXF2;FOXCUT	0.63	0.59	- 1.121	0.82	40.735	0.51
chr9	107695848	Intergenic	U	A	ABCA1;SLC44A1	0.61	0.65	1.095	0.69	6.970	0.49
chr9	107695353	Intergenic	U	A	ABCA1;SLC44A1	0.61	0.64	0.690	0.69	6.970	0.47
chr9	107703934	Intergenic	U	A	ABCA1;SLC44A1	0.6	0.48	- 7.836	0.83	58.058	0.49
chr6	1548369	Intergenic	A	0	FOXF2;FOXCUT	0.36	0.38	0.395	0.15	- 52.096	0.49
chr4	7896213	Intronic	A	0	AFAP1	0.66	0.59	— 3.016	0.72	4.381	0.68
chr4	7846240	Intronic	U	F	AFAP1	0.32	0.38	2.332	0.15	- 36.294	0.29
chr4	7891545	Intronic	A	U	AFAP1	0.29	0.32	0.743	0.14	- 30.033	0.18
chr6	170454915	Intergenic	A	U	LINC00574;LOC102724511	0.8	0.82	0.502	0.74	- 5.373	0.76
chr6	170464367	Intergenic	U	A	LINC00574;LOC102724511	0.61	0.58	— 0.664	0.7	8.654	0.5
chr5	14820927	Intronic	U	F	ANKH	0.29	0.34	1.752	0.28	- 0.298	0.33
chr7	80838977	Intergenic	A	5	SEMA3C;LOC105369146	0.71	0.68	— 0.743	0.81	12.896	0.91
chr14	60976537	Exonic	U	A	SIX6	0.34	0.66	54.967	0.032	- 143.370	0.21
chr16	8896931	Intronic	A	U	PMM2	0.18	0.14	- 1.712	0.096	- 13.535	0.28
chr10	60338753	Intronic	Т	U	BICC1	0.49	0.32	— 15.716	0.55	3.871	0.48
chr7	116162729	Intergenic	U	A	CAV2;CAV1	0.23	0.21	— 0.434	0.4	32.449	0.0099
chr7	115810676	Intergenic	A	J	TFEC;TES	0.54	0.43	- 6.518	0.61	5.149	0.8
	Chr chr3 chr3 chr3 chr4 chr3 chr6 chr6 chr3	Chr Position chr7 117603820 chr7 117603820 chr8 116151338 chr14 61072875 chr14 61072875 chr14 61072875 chr14 61072875 chr14 61072875 chr14 1062714416 chr11 120340383 chr11 120340383 chr14 60847001 chr16 12933116 chr16 17635353 chr16 107695848 chr6 107703934 chr6 1076953535 chr6 107703934 chr6 107703934 chr6 107703934 chr6 1076955353 chr6 107703934 chr6 107703934	Chr Position Type chr7 117603820 Intergenic chr14 61072875 Intergenic chr14 61072875 Intergenic chr14 61072875 Intergenic chr11 108278616 Intronic chr11 10827816 Intronic chr11 120340383 Intronic chr11 120340383 Intronic chr11 120340383 Intronic chr11 120340383 Intronic chr3 15005942 Intergenic chr3 15005942 Intergenic chr4 11679113 Intronic chr4 11679113 Intronic chr6 51406848 Intergenic chr6 12933532 Intergenic chr6 1533116 Intergenic chr6 107695353 Intergenic chr6 107695353 Intergenic chr6 107695353 Intergenic chr6 1076953535 </td <td>ChrPositionTypeRef Allelechr7117603820IntergenicGchr1116151338IntergenicGchr1461072875IntergenicTchr1461072875IntergenicTchr11108278616IntronicTchr1110323833IntronicGchr11120340383IntronicGchr11120340383IntronicGchr315005942IntronicGchr315005942IntronicGchr315005942IntronicGchr315005942IntronicGchr311679113IntronicGchr3108251139IntronicGchr651406848IntergenicGchr3108251139IntronicGchr611653025IntergenicGchr615334652IntronicGchr6107203934IntergenicGchr6116530253IntergenicGchr6170464367IntronicGchr6170464367IntronicGchr6170464367IntronicGchr6170464367IntronicGchr6170464367IntronicGchr6170464367IntronicGchr6170464367IntronicGchr6170464367IntronicGchr6170464367IntronicGchr6<!--</td--><td>ChrPositionTypeRef AlleleAt Allelechr7117603820IntergenicTCchr1461072875IntergenicTCchr1461072875IntergenicTCchr11165714416IntronicCAchr11165714416IntronicCAchr11120340383IntronicCAchr11120340383IntronicCAchr11120340383IntronicCTchr315005942IntronicCTchr315005942IntronicAGchr315005942IntronicAGchr311679113IntronicAGchr311679113IntronicAGchr311679133IntronicAGchr311679133IntronicAGchr311679133IntronicAGchr411679133IntronicAGchr4116793025IntronicAGchr6133465IntronicAGchr6111653023IntronicAGchr61333653IntronicAGchr6133316IntronicAGchr61333653IntronicAGchr61333653IntronicAGchr61333653IntronicAGchr61333653</td><td>ChrPositionTypeRef AlleleAlt AlleleNarby/containing Genechr/1117603820IntergenicTCCTTNBP2JSM8chr/11151333IntergenicTCCM2ZCAVIchr/116151333IntergenicTCCM2ZCAVIchr/31053320IntergenicTCCM2ZCAVIchr/1165714416IntronicTCSYSSALRNA1chr/1155714416IntronicCAANGFT1chr/11597133IntronicGAANGFT1chr/11597133IntronicGACM2C012455202chr/31590433IntronicGAANGFT1chr/31597310IntronicGACM2C012455202chr/315973139IntronicAGANGFT1chr/315973139IntronicAGANGFT1chr/315973139IntronicAGANGFT1chr/315973139IntronicAGANGT1chr/31597332IntronicAGANGT1chr/31537453IntronicAGANGT1chr/3153733IntronicACCchr/31537333IntronicACCchr/31533328IntronicACCchr/3153333IntronicACCchr/31533333IntronicACC</td><td></td><td>Chr Position Type Ref.Allele Ait.Allele Ait.Allele</td><td>Chr Position Type Ref Allele At Allele Net Allelee Net Alleeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeee</td><td>Chr Pisition Type Rel Allele Art Allele Nat Allelee Nat Allelee Nat Allelee</td><td>Cir Position Type Rel Auleie Analyticamunity Gene Golal EAF AMR Ray AMR Ray ATR Ray ATR Ray ch1 17/30380 Integretic T C CVCACMI 0.23 0.23 0.23 0.739 ch1 17/30380 Integretic T C CVCACMI 0.23 0.23 0.23 0.739 ch1 18/274616 Intergretic T C CVCACMI 0.23 0.23 0.23 0.23 0.739 ch1 18/274616 Intergretic C AMGT1 0.13 0.23 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.0</td></td>	ChrPositionTypeRef Allelechr7117603820IntergenicGchr1116151338IntergenicGchr1461072875IntergenicTchr1461072875IntergenicTchr11108278616IntronicTchr1110323833IntronicGchr11120340383IntronicGchr11120340383IntronicGchr315005942IntronicGchr315005942IntronicGchr315005942IntronicGchr315005942IntronicGchr311679113IntronicGchr3108251139IntronicGchr651406848IntergenicGchr3108251139IntronicGchr611653025IntergenicGchr615334652IntronicGchr6107203934IntergenicGchr6116530253IntergenicGchr6170464367IntronicGchr6170464367IntronicGchr6170464367IntronicGchr6170464367IntronicGchr6170464367IntronicGchr6170464367IntronicGchr6170464367IntronicGchr6170464367IntronicGchr6170464367IntronicGchr6 </td <td>ChrPositionTypeRef AlleleAt Allelechr7117603820IntergenicTCchr1461072875IntergenicTCchr1461072875IntergenicTCchr11165714416IntronicCAchr11165714416IntronicCAchr11120340383IntronicCAchr11120340383IntronicCAchr11120340383IntronicCTchr315005942IntronicCTchr315005942IntronicAGchr315005942IntronicAGchr311679113IntronicAGchr311679113IntronicAGchr311679133IntronicAGchr311679133IntronicAGchr311679133IntronicAGchr411679133IntronicAGchr4116793025IntronicAGchr6133465IntronicAGchr6111653023IntronicAGchr61333653IntronicAGchr6133316IntronicAGchr61333653IntronicAGchr61333653IntronicAGchr61333653IntronicAGchr61333653</td> <td>ChrPositionTypeRef AlleleAlt AlleleNarby/containing Genechr/1117603820IntergenicTCCTTNBP2JSM8chr/11151333IntergenicTCCM2ZCAVIchr/116151333IntergenicTCCM2ZCAVIchr/31053320IntergenicTCCM2ZCAVIchr/1165714416IntronicTCSYSSALRNA1chr/1155714416IntronicCAANGFT1chr/11597133IntronicGAANGFT1chr/11597133IntronicGACM2C012455202chr/31590433IntronicGAANGFT1chr/31597310IntronicGACM2C012455202chr/315973139IntronicAGANGFT1chr/315973139IntronicAGANGFT1chr/315973139IntronicAGANGFT1chr/315973139IntronicAGANGT1chr/31597332IntronicAGANGT1chr/31537453IntronicAGANGT1chr/3153733IntronicACCchr/31537333IntronicACCchr/31533328IntronicACCchr/3153333IntronicACCchr/31533333IntronicACC</td> <td></td> <td>Chr Position Type Ref.Allele Ait.Allele Ait.Allele</td> <td>Chr Position Type Ref Allele At Allele Net Allelee Net Alleeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeee</td> <td>Chr Pisition Type Rel Allele Art Allele Nat Allelee Nat Allelee Nat Allelee</td> <td>Cir Position Type Rel Auleie Analyticamunity Gene Golal EAF AMR Ray AMR Ray ATR Ray ATR Ray ch1 17/30380 Integretic T C CVCACMI 0.23 0.23 0.23 0.739 ch1 17/30380 Integretic T C CVCACMI 0.23 0.23 0.23 0.739 ch1 18/274616 Intergretic T C CVCACMI 0.23 0.23 0.23 0.23 0.739 ch1 18/274616 Intergretic C AMGT1 0.13 0.23 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.0</td>	ChrPositionTypeRef AlleleAt Allelechr7117603820IntergenicTCchr1461072875IntergenicTCchr1461072875IntergenicTCchr11165714416IntronicCAchr11165714416IntronicCAchr11120340383IntronicCAchr11120340383IntronicCAchr11120340383IntronicCTchr315005942IntronicCTchr315005942IntronicAGchr315005942IntronicAGchr311679113IntronicAGchr311679113IntronicAGchr311679133IntronicAGchr311679133IntronicAGchr311679133IntronicAGchr411679133IntronicAGchr4116793025IntronicAGchr6133465IntronicAGchr6111653023IntronicAGchr61333653IntronicAGchr6133316IntronicAGchr61333653IntronicAGchr61333653IntronicAGchr61333653IntronicAGchr61333653	ChrPositionTypeRef AlleleAlt AlleleNarby/containing Genechr/1117603820IntergenicTCCTTNBP2JSM8chr/11151333IntergenicTCCM2ZCAVIchr/116151333IntergenicTCCM2ZCAVIchr/31053320IntergenicTCCM2ZCAVIchr/1165714416IntronicTCSYSSALRNA1chr/1155714416IntronicCAANGFT1chr/11597133IntronicGAANGFT1chr/11597133IntronicGACM2C012455202chr/31590433IntronicGAANGFT1chr/31597310IntronicGACM2C012455202chr/315973139IntronicAGANGFT1chr/315973139IntronicAGANGFT1chr/315973139IntronicAGANGFT1chr/315973139IntronicAGANGT1chr/31597332IntronicAGANGT1chr/31537453IntronicAGANGT1chr/3153733IntronicACCchr/31537333IntronicACCchr/31533328IntronicACCchr/3153333IntronicACCchr/31533333IntronicACC		Chr Position Type Ref.Allele Ait.Allele Ait.Allele	Chr Position Type Ref Allele At Allele Net Allelee Net Alleeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeee	Chr Pisition Type Rel Allele Art Allele Nat Allelee Nat Allelee Nat Allelee	Cir Position Type Rel Auleie Analyticamunity Gene Golal EAF AMR Ray AMR Ray ATR Ray ATR Ray ch1 17/30380 Integretic T C CVCACMI 0.23 0.23 0.23 0.739 ch1 17/30380 Integretic T C CVCACMI 0.23 0.23 0.23 0.739 ch1 18/274616 Intergretic T C CVCACMI 0.23 0.23 0.23 0.23 0.739 ch1 18/274616 Intergretic C AMGT1 0.13 0.23 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.0

Table 1 (cor	ntinued)												
SNP ID	Chr	Position	Type	Ref All	ele Alt,	Allele Nearby/containing	Gene Glot	oal EAF	AMR EAF	AMR log ₁₀ P	AFR EAF	AFR log ₁₀ P	EAS EAF
rs5756813	chr22	38175477	Intergenic	5	F	TRIOBP;H1F0	0.55		0.62	2.799	0.4	- 21.169	0.71
rs58073046	chr11	120248493	Intronic	A	U	ARHGEF12	0.1		0.042	- 6.316	0.013	- 32.104	0.17
rs61394862	chr5	14851094	Intronic	U	⊢	ANKH	0.28		0.33	1.781	0.26	- 0.777	0.32
rs6478746	chr9	129367398	Intergenic	0	∢	MVB12B;LMX1B	0.8		0.85	2.421	0.73	- 6.990	0.97
rs66602224	chr8	108293718	Intronic	U	A	ANGPT1	0.32		0.32	0.000	0.44	14.831	0.14
rs6732795	chr2	69411517	Intronic	A	U	ANTXR1	0.66		0.49	- 16.002	0.78	16.515	0.85
rs73174345	chr3	169252883	Intronic	⊢	U	MECOM	0.05	4	0.036	- 1.095	0.13	18.287	0
rs746491	chr11	86406159	Intergenic	U	¢	ME3;PRSS23	0.15		0.17	0.588	0.11	— 3.715	0.14
rs7518099	chr1	165736880	Intronic	υ	⊢	TMC01	0.92		0.87	- 3.857	0.91	- 0.608	0.99
rs7555523	chr1	165718979	Intronic	υ	A	TMC01	0.0		0.87	- 1.399	0.85	- 6.009	0.99
rs7924522	chr11	1 28380742	Intronic	υ	A	ETS1	0.75		0.71	- 1.291	0.79	2.503	0.86
rs8141433	chr22	19854006	Intergenic	A	U	GNB1L;TXNRD2	0.28		0.16	- 10.572	0.69	159.128	0.037
rs9284802	chr3	85095766	Intronic	U	A	CADM2	0.32		0.33	0.177	0.13	- 46.150	0.17
rs945686	chr9	1 29378026	Intronic	U	U	LMX1B	0.82		0.87	2.585	0.73	- 11.619	0.99
rs9494457	chr6	136474794	Intronic	F	A	PDE78	0.39	-	0.45	2.158	0.37	- 0.696	0.33
rs9853115	chr3	186131600	Intergenic	F	A	DGKG;LINC02052	0.56		0.47	- 4.386	0.48	— 6.471	0.73
rs9913911	chr17	10031183	Intronic	Þ	U	GAS7	0.31		0.32	0.177	0.16	— 28.132	0.5
SNP ID	Chr	Position	Type	Ref Allele	Alt Allele	Nearby/containing Gene	EAS log ₁₀ P	SAS EAF	SAS log ₁₀ F	P EUREAF	EUR log ₁₀ P	KOR EAF	KOR log ₁₀ P
rs1013278	chr7	117603820	Intergenic	U	U	CTTNBP2;LSM8	- 47.563	0.4	6.676	0.4	7.043	0.114	- 102.924
rs10281637	chr7	116151338	Intergenic	Т	U	CAV2;CAV1	- 80.906	0.19	- 1.271	0.26	2.100	0.007	- 232.094
rs10483727	chr14	61072875	Intergenic	F	U	SIX6;SALRNA1	- 17.809	0.42	4.030	0.6	47.063	0.271	- 13.494
rs10505100	chr8	108278616	Intronic	U	A	ANGPT1	6.644	0.2	2.350	0.11	- 4.159	0.283	40.539
rs10918274	chr1	165714416	Intronic	Т	U	TMC01	20.362	0.96	5.017	0.86	- 7.783	0.993	62.418
rs11217878	chr11	120340383	Intronic	IJ	A	ARHGEF12	1.395	0.23	0.659	0.16	- 3.413	0.227	1.147
rs113985657	chr6	597203	Intronic	U	⊢	EXOC2	1.036	0.12	0.000	0.14	1.014	0.208	26.399
rs11710139	chr3	150059342	Intergenic	IJ	A	LINC01214;TSC22D2	- 12.606	0.16	0.000	0.23	6.403	0.096	- 16.719
rs12377624	chr9	129373110	Intergenic	IJ	U	MVB12B;LMX1B	- 12.549	0.33	9.258	0.37	18.120	0.079	- 78.578
rs1254276	chr14	60847001	Intergenic	U	μ	LINC02322;C14orf39	19.784	0.6	— 0.943	0.4	- 39.746	0.727	19.784
rs12699251	chr7	11679113	Intronic	A	U	THSD7A	- 3.064	0.25	0.000	0.4	19.691	0.229	- 1.524
rs1579050	chr2	153364527	Intronic	A	U	FMNL2	- 89.083	0.35	4.372	0.58	69.618	0.025	- 242.856
rs17752199	chr6	51406848	Intergenic	A	U	TFAP2B;PKHD1	- 0.364	0.12	- 0.327	0.12	- 0.320	0.103	- 3.773
rs1874458	chr16	65080739	Intronic	IJ	A	CDH11	0.314	0.2	0.000	0.33	17.034	0.250	7.076
rs2022945	chr8	108251139	Intergenic	A	ט	ABRA;ANGPT1	- 6.644	0.8	- 2.350	0.89	4.159	0.723	- 37.209

Table 1 (co	ntinued)												
SNP ID	Chr	Position	Type	Ref Allele	Alt Allele	Nearby/containing Gene	EAS log ₁₀ P	SAS EAF	SAS log ₁₀ P	EUR EAF	EUR log ₁₀ P	KOR EAF	KOR log ₁₀ P
rs2024211	chr7	116153025	Intergenic	A	υ	CAV2;CAV1	- 76.273	0.19	- 0.664	0.26	3.118	0.007	- 218.926
rs2073006	chr6	637465	Intronic	U	Γ	EXOC2	3.236	0.11	0.000	0.13	1.060	0.220	40.976
rs2188836	chr7	117635382	Intergenic	U	T	CTTNBP2;LSM8	- 60.936	0.43	7.936	0.41	5.477	0.095	- 150.366
rs2317961	chr6	1533116	Intergenic	A	U	FOXF2;FOXCUT	- 11.567	0.52	- 8.961	0.64	0.217	0.475	- 44.116
rs2472493	chr9	107695848	Intergenic	U	A	ABCA1;SLC44A1	- 11.416	0.65	1.567	0.58	- 1.060	0.460	- 40.945
rs2472496	chr9	107695353	Intergenic	U	A	ABCA1;SLC44A1	- 15.152	0.67	3.051	0.58	- 1.060	0.428	- 59.932
rs2487032	chr9	107703934	Intergenic	U	A	ABCA1;SLC44A1	- 9.692	0.56	— 1.474	0.5	- 7.924	0.476	- 28.298
rs2745572	chr6	1548369	Intergenic	A	U	FOXF2;FOXCUT	13.501	0.48	10.620	0.36	0.000	0.517	45.723
rs28500712	chr4	7896213	Intronic	A	U	AFAP1	0.586	0.54	- 10.735	0.72	3.416	0.709	5.547
rs28520091	chr4	7846240	Intronic	U	F	AFAP1	- 1.186	0.37	2.314	0.5	25.369	0.295	- 1.770
rs28795989	chr4	7891545	Intronic	A	IJ	AFAP1	- 12.655	0.26	- 1.084	0.6	73.748	0.170	- 36.886
rs2935057	chr6	170454915	Intergenic	A	IJ	LINC00574;LOC102724511	- 2.238	0.84	2.252	0.88	8.761	0.729	- 13.364
rs3013274	chr6	170464367	Intergenic	IJ	A	LINC00574;LOC102724511	- 9.753	0.68	4.063	0.57	- 1.606	0.428	- 59.784
rs31918	chr5	14820927	Intronic	U	F	ANKH	1.881	0.22	- 4.799	0.29	0.000	0.334	4.776
rs327716	chr7	80838977	Intergenic	A	IJ	SEMA3C;LOC105369146	45.585	0.64	- 4.367	0.43	- 60.462	0.947	183.742
rs33912345	chr14	60976537	Exonic	U	A	SIX6	- 15.632	0.4	3.083	0.6	50.841	0.268	- 11.500
rs3785176	chr16	8896931	Intronic	A	U	PMM2	11.463	0.13	- 3.575	0.25	660.9	0.316	45.623
rs4141671	chr10	60338753	Intronic	F	U	BICC1	- 0.226	0.56	3.867	0.49	0.000	0.489	- 0.037
rs4236601	chr7	116162729	Intergenic	U	A	CAV2;CAV1	— 84.231	0.19	- 1.952	0.26	1.262	0.007	— 244.996
rs55892100	chr7	115810676	Intergenic	A	U	TFEC;TES	54.802	0.43	- 8.650	0.37	- 21.708	0.835	182.195
rs5756813	chr22	38175477	Intergenic	IJ	F	TRIOBP;H1F0	20.456	0.5	- 2.095	0.58	0.989	0.643	16.731
rs58073046	chr11	120248493	Intronic	A	IJ	ARHGEF12	8.745	0.21	17.513	0.1	0.000	0.168	18.725
rs61394862	chr5	14851094	Intronic	U	L	ANKH	1.910	0.21	- 4.971	0.28	0.000	0.333	6.636
rs6478746	chr9	129367398	Intergenic	U	A	MVB12B;LMX1B	50.342	0.78	- 0.668	0.7	— 10.654	0.967	127.390
rs66602224	chr8	108293718	Intronic	U	A	ANGPT1	- 32.704	0.28	- 1.639	0.4	5.548	0.204	- 31.901
rs6732795	chr2	69411517	Intronic	A	U	ANTXR1	34.845	0.68	0.540	0.4	- 50.841	0.900	152.394
rs73174345	chr3	169252883	Intronic	\perp	U	MECOM	- 21.410	0.014	- 7.882	0.059	0.230	0.000	— 59.854
rs746491	chr11	86406159	Intergenic	U	A	ME3;PRSS23	- 0.338	0.13	- 0.815	0.21	5.097	0.193	6.653
rs7518099	chr1	165736880	Intronic	U	L	TMC01	20.362	0.96	5.017	0.86	- 7.783	0.993	63.362
rs7555523	chr1	165718979	Intronic	U	A	TMC01	27.970	0.96	9.258	0.86	- 3.391	0.993	85.262
rs7924522	chr11	128380742	Intronic	U	A	ETS1	14.150	0.75	0.000	0.63	- 13.128	0.907	78.316
rs8141433	chr22	19854006	Intergenic	A	U	GNB1L;TXNRD2	— 78.658	0.22	- 3.655	0.15	— 18.042	0.040	- 200.793
rs9284802	chr3	85095766	Intronic	U	A	CADM2	- 22.155	0.41	6.585	0.63	72.241	0.176	- 49.830
rs945686	chr9	129378026	Intronic	J	U	LMX1B	61.221	0.79	- 1.348	0.76	- 4.495	0.987	156.676

Shin et al. BMC Med Genomics (2021) 14:80

Table 1 (c	continued	(
SNP ID	Chr	Position	Type	Ref Allele	Alt Allele	Nearby/containing Gene	EAS log ₁₀ P	SAS EAF	SAS log ₁₀ P	EUR EAF
rs9494457	chr6	136474794	Intronic	μ	A	PDE78	- 3.323	0.44	2.158	0.37

KOR log₁₀ P

KOR EAF

EUR log₁₀ P

rs9494457	chr6	136474794	Intronic	F	A	PDE78	- 3.323	0.44	2.158	0.37	- 0.570	0.282	- 23.733
rs9853115	chr3	186131600	Intergenic	T	A	DGKG;LINC02052	23.247	0.57	0.193	0.53	- 1.014	0.701	38.881
rs9913911	chr17	10031183	Intronic	A	0	GAS7	28.572	0.27	- 1.662	0.37	3.416	0.554	109.722
Chr: chromosor Fischer's test, st	ne EAF: effe atistical sigr	ect allele frequer nificance was se	ncy ref allele: r∈ t at P<0.05 and	eference alle d log ₁₀ <i>P</i> >1	le alt allele: alt 1.301	erative allele AMR: Americans AFF	R: Africans, EAS: I	East Asians, S	AS: South Asians	, EUR: Europe	eans, KOR: Korea	ns, <i>P-</i> value: a	djusted



groups. The hierarchical clustering tree showed the differences among the populations; Europeans, Americans, and South Asians were in one cluster, and Africans, East Asians, and Koreans were in another cluster. In addition, we compared the EAFs of East Asians and Koreans (Additional file 3: Table S2, Additional file 1: Figure S2). Although the EAF was not much different among East Asians, 25 SNPs were enriched, 26 SNPs were depleted, and 84 SNPs were similar to those in Koreans. Moreover, the heatmap clearly showed that the main pattern of the allele frequency in East Asians in the 1000 Genomes Project was very similar to that in Koreans, while few alleles showed the opposite pattern in allele frequency between East Asians and Koreans.

Patterns of IOP elevation-related OAG risk alleles among populations

Fifty-two IOP-related SNP traits were selected from 135 OAG-related SNPs (Table 1), and a heatmap showing how significantly the EAF was enriched or depleted across the Koreans and continental groups (Fig. 2) with a log scale among 52 IOP-related SNPs was generated. For Koreans, 23 OAG-related SNPs were significantly enriched, 27 SNPs depleted, and 2 SNPs were similar to global EAF. For example, rs2024211, located in the Intergenic of CAV2; CAV1 that is expressed in the trabecular meshwork cells cultured from OAG eyes and encoding Caveolins [34], has T/C alleles in which the C allele was tested in European populations to identify the risk of OAG with high IOP [25]. The C allele frequencies were 26%, 36%, and 0.7% in European, African, and Korean populations, respectively. Further, rs1579050, located in FMNL2 gene belongs to the formin-related family of proteins that acts as a downstream effector of CDC42 (Rho family member) [33], has A/G alleles in which the G allele frequencies were 58%, 10%, and 2.5% in European, African, and Korean populations. The rs8141433, located in the Intergenic of GNB1L; TXNRD2, TXNRD2 gene encodes a mitochondrial protein required for redox homeostasis [35], revealed the G allele frequencies of 15%, 69%, and 4% in European, African, and Korean populations. A hierarchical clustering tree showed the differences among the populations; Europeans, Americans, and South Asians were in one cluster, and Africans, East Asians, and Koreans were in another cluster. These allele frequencies may be related to a difference in the NTG proportion of OAG among the populations. In addition, a heatmap showed how significantly the EAF was enriched or depleted across the Koreans and East Asians (Table 2, Fig. 3). For Koreans, rs12377624, LMX1B gene had G/C alleles in which the C allele frequencies were 14%, 12.5%, and 7.9% in Chinese, Japanese, and Koreans, respectively, whereas, rs2073006, EXOC2 gene had C/T alleles in which the T allele frequencies were 11.8%, 8.1%, and 22.0% in Chinese, Vietnamese, and Koreans, respectively. However, the EAF was not much different among East Asians; for Koreans, 13 SNPs were enriched, 7 SNPs were depleted, and 32 SNPs were similar to those in Global East Asians. A hierarchical clustering tree showed the differences among East Asians, KOR, Japanese, and Han Chinese in Beijing in one cluster, and Southern Han Chinese and Chinese Dai in Xishuangbanna in another cluster.

Composite genetic risk scores calculated using SNPs related to OAG as whole and OAG with high IOP

We calculated the composite genetic risk scores based on copies of effect alleles at OAG-associated SNPs, with the assumption that allelic associations from a significant majority of GWAS-identified variants can be replicated in non-European populations [36]. The genetic risk score of OAG was highest in Africans, followed by Europeans, South Asians, and East Asians (Fig. 4). The prevalence of OAG was correlated with the population average genetic risk score (R=0.293, Fig. 4). In addition, the genetic risk score of OAG with high IOP was highest in Europeans, followed by South Asians, Africans, and East Asians (Fig. 5). The prevalence of OAG with elevated IOP was positively correlated with the population average genetic risk score (R=0.699, Fig. 5).

Discussion

Genetic factors are likely to play an essential role in the development of OAG [37]. Well-designed glaucoma cohort studies [23–26] had demonstrated the

ans
Dre
ž
ding
g
Ë.
sdn
Jo
UD UD
Asia
ast ,
Ĕ
is ir
ism
þ
noi
J/r
ď
tide
e0.
JUC
e_
ing
d s
late
e U
iure
ess
r p
ula
aoc
nträ
ofi
Fs)
ĒĀ
es
in ci
b
fre
ele
alle
fect
Eff
а 2
q
Ë

0.000 0.000 0.381						Internanic G CTTNIBD4 SM8 01 0106 0000		
1	0105	0105	CTTNIBD34 SM0 01 01 010E				ווזהטספלת ווונבולבנוור מירי רייר רוואסרק,בטאוס טון טון טוןטס	Abril 117603030 Intervention C CTTANBD34 CMG 01 010E
	0.105 (0.1 0.105 (CTTNBP2;LSM8 0.1 0.105 0.	C CTTNBP2,LSM8 0.1 0.105 C	G C CTTNBP2;LSM8 0.1 0.105 C	ווויבואבוויר ס ר רווואחנילידאאוס מיו מיוחס ר		chr7 117603820 Intergenic G C CTTNBP2,LSM8 0.1 0.105 (
0	0.005 0	0.0089 0.005 0	CAV2;CAV1 0.0089 0.005 0	C CAV2;CAV1 0.0089 0.005 0	T C CAV2;CAV1 0.0089 0.005 0	Intergenic T C CAV2;CAV1 0.0089 0.005 0	116151338 Intergenic T C CAV2;CAV1 0.0089 0.005 0	chr7 116151338 Intergenic T C CAV2;CAV1 0.0089 0.005 0
	0.167 - 0.3	0.21 0.167 - 0.3	SIX6;SALRNA1 0.21 0.167 – 0.3	C SIX6;SALRNA1 0.21 0.167 – 0.3	T C SIX6;SALRNA1 0.21 0.167 – 0.3	Intergenic T C SIX6;SALRNA1 0.21 0.167 – 0.3	61072875 Intergenic T C SIX6;SALRNA1 0.21 0.167 – 0.3	chr14 61072875 Intergenic T C SIX6;SALRNA1 0.21 0.167 – 0.3
0.0	0.233 0.00	0.23 0.233 0.00	ANGPT1 0.23 0.23 0.00	A ANGPT1 0.23 0.233 0.00	C A ANGPT1 0.23 0.23 0.00	Intronic C A ANGPT1 0.23 0.23 0.00	108278616 Intronic C A ANGPT1 0.23 0.23 0.00	chr8 108278616 Intronic C A ANGPT1 0.23 0.23 0.00
0.0	0.976 — 0.0	0.99 0.976 - 0.04	TMCO1 0.99 0.976 - 0.0-	C TMCO1 0.99 0.976 – 0.0-	T C TMCO1 0.99 0.976 – 0.0-	Intronic T C TMCO1 0.99 0.976 - 0.0-	165714416 Intronic T C TMCO1 0.99 0.976 -0.0	chr1 165714416 Intronic T C TMCO1 0.99 0.976 – 0.0-
0.0	0.224 0.00	0.24 0.224 0.00	ARHGEF12 0.24 0.224 0.00	A ARHGEF12 0.24 0.224 0.00	G A ARHGEF12 0.24 0.224 0.00	Intronic G A ARHGEF12 0.24 0.224 0.00	120340383 Intronic G A ARHGEF12 0.24 0.20	chr11 120340383 Intronic G A ARHGEF12 0.24 0.224 0.00
0.0	0.167 0.0	0.14 0.167 0.0	EXOC2 0.14 0.167 0.0	T EXOC2 0.14 0.167 0.0	C T EXOC2 0.14 0.167 0.0	Intronic C T EXOC2 0.14 0.167 0.0	597203 Intronic C T EXOC2 0.14 0.167 0.0	chr6 597203 Intronic C T EXOC2 0.14 0.167 0.0
0.0	0.071 0.0	0.075 0.071 0.0	LINC01214;TSC22D2 0.075 0.071 0.0	A LINC01214;TSC22D2 0.075 0.071 0.0	G A LINC01214;TSC22D2 0.075 0.071 0.0	Intergenic G A LINC01214;TSC22D2 0.075 0.071 0.0	150059342 Intergenic G A LINC01214;TSC22D2 0.075 0.071 0.0	chr3 150059342 Intergenic G A LINC01214;TSC22D2 0.075 0.071 0.0
0.00	0.114 0.00	0.13 0.114 0.00	MVB12B,LMX1B 0.13 0.114 0.00	C MVB12B;LMX1B 0.13 0.114 0.00	G C MVB12B;LMX1B 0.13 0.114 0.00	Intergenic G C MVB12B;LMX1B 0.13 0.114 0.00	129373110 Intergenic G C MVB12B;LMX1B 0.13 0.114 0.00	chr9 129373110 Intergenic G C MVB12B,LMX1B 0.13 0.114 0.00
0.126	0.833 0.126	0.78 0.833 0.126	LINC02322;C14orf39 0.78 0.833 0.126	T LINC02322;C14orf39 0.78 0.833 0.126	C T LINC02322;C14orf39 0.78 0.833 0.126	Intergenic C T LINC02322;C14orf39 0.78 0.833 0.126	60847001 Intergenic C T LINC02322;C14orf39 0.78 0.833 0.126	chr14 60847001 Intergenic C T LINC02322;C14orf39 0.78 0.833 0.126
000.0	0.224 0.000	0.2 0.224 0.000	THSD7A 0.224 0.000	G THSD7A 0.2 0.224 0.000	A G THSD7A 0.2 0.224 0.000	Intronic A G THSD7A 0.2 0.224 0.000	11679113 Intronic A G THSD7A 0.20 0.224 0.000	chr7 11679113 Intronic A G THSD7A 0.2 0.224 0.000
0.000	0.010 0.000	0.026 0.010 0.000	FMNL2 0.026 0.010 0.000	G FMNL2 0.026 0.010 0.000	A G FMNL2 0.026 0.010 0.000	Intronic A G FMNL2 0.026 0.010 0.000	153364527 Intronic A G FMNL2 0.026 0.010 0.000	chr2 153364527 Intronic A G FMNL2 0.026 0.010 0.000
0.000	0.105 0.000	0.12 0.105 0.000	TFAP2B;PKHD1 0.12 0.105 0.000	G TFAP2B;PKHD1 0.12 0.105 0.000	A G TFAP28;PKHD1 0.12 0.105 0.000	Intergenic A G TFAP2B;PKHD1 0.12 0.105 0.000	51406848 Intergenic A G TFAP28;PKHD1 0.12 0.105 0.000	chr6 51406848 Intergenic A G TFAP28;PKHD1 0.12 0.105 0.000
0.000	0.229 0.000	0.21 0.229 0.000	CDH11 0.21 0.229 0.000	A CDH11 0.21 0.229 0.000	G A CDH11 0.21 0.229 0.000	Intronic G A CDH11 0.21 0.229 0.000	65080739 Intronic G A CDH11 0.21 0.229 0.000	chr16 65080739 Intronic G A CDH11 0.21 0.229 0.000
0.00	0.762 0.00	0.77 0.762 0.00	ABRA;ANGPT1 0.77 0.762 0.00	G ABRA;ANGPT1 0.77 0.762 0.00	A G ABRA;ANGPT1 0.77 0.762 0.00	Intergenic A G ABRA;ANGPT1 0.77 0.762 0.00	108251139 Intergenic A G ABRA;ANGPT1 0.77 0.762 0.00	chr8 108251139 Intergenic A G ABRA;ANGPT1 0.77 0.762 0.00
0.0	0.005 0.00	0.0089 0.005 0.00	CAV2;CAV1 0.0089 0.005 0.00	C CAV2;CAV1 0.0089 0.005 0.0	A C CAV2;CAV1 0.0089 0.005 0.0	Intergenic A C CAV2;CAV1 0.0089 0.005 0.0	116153025 Intergenic A C CAV2;CAV1 0.0089 0.005 0.00	chr7 116153025 Intergenic A C CAV2;CAV1 0.0089 0.005 0.0
0.0	0.181 0.0	0.15 0.181 0.04	EXOC2 0.15 0.181 0.04	T EXOC2 0.15 0.181 0.0-	C T EXOC2 0.15 0.181 0.0-	Intronic C T EXOC2 0.15 0.181 0.0-	637465 Intronic C T EXOC2 0.15 0.181 0.0-	chr6 637465 Intronic C T EXOC2 0.15 0.181 0.04
0.0	0.076 0.00	0.09 0.076 0.00	CTTNBP2;LSM8 0.09 0.076 0.00	T CTTNBP2;LSM8 0.09 0.076 0.00	C T CTTNBP2;LSM8 0.09 0.076 0.00	Intergenic C T CTTNBP2;LSM8 0.09 0.076 0.00	117635382 Intergenic C T CTTNBP2;LSM8 0.09 0.076 0.00	chr7 117635382 Intergenic C T CTTNBP2;LSM8 0.09 0.076 0.00
0.0	0.519 0.00	0.51 0.519 0.00	FOXF2;FOXCUT 0.51 0.519 0.00	G FOXF2;FOXCUT 0.51 0.519 0.00	A G FOXF2;FOXCUT 0.51 0.519 0.0	Intergenic A G FOXF2;FOXCUT 0.51 0.519 0.00	1533116 Intergenic A G FOXF2;FOXCUT 0.51 0.519 0.0	chr6 1533116 Intergenic A G FOXF2;FOXCUT 0.51 0.519 0.00
0.0	0.471 0.00	0.49 0.471 0.00	ABCA1;SLC44A1 0.49 0.471 0.00	A ABCA1;SLC44A1 0.49 0.471 0.0	G A ABCA1;SLC44A1 0.49 0.471 0.00	Intergenic G A ABCA1;SLC44A1 0.49 0.471 0.00	107695848 Intergenic G A ABCA1,5LC44A1 0.49 0.471 0.0	chr9 107695848 Intergenic G A ABCA1,5LC44A1 0.49 0.471 0.0
0.00	0.457 0.000	0.47 0.457 0.000	ABCA1;SLC44A1 0.47 0.457 0.000	A ABCA1;SLC44A1 0.47 0.457 0.000	G A ABCA1;SLC44A1 0.47 0.457 0.000	Intergenic G A ABCA1;5LC44A1 0.47 0.457 0.000	107695353 Intergenic G A ABCA1;SLC44A1 0.47 0.457 0.000	chr9 107695353 Intergenic G A ABCA1;SLC44A1 0.47 0.457 0.000
0.000	0.467 0.000	0.49 0.467 0.000	ABCA1;SLC44A1 0.49 0.467 0.000	A ABCA1;SLC44A1 0.49 0.467 0.000	G A ABCA1;SLC44A1 0.49 0.467 0.000	Intergenic G A ABCA1;SLC44A1 0.49 0.467 0.000	107703934 Intergenic G A ABCA1;SLC44A1 0.49 0.467 0.000	chr9 107703934 Intergenic G A ABCA1;SLC44A1 0.49 0.467 0.000
0.000	0.481 0.000	0.49 0.481 0.000	FOXF2;FOXCUT 0.49 0.481 0.000	G FOXF2;FOXCUT 0.49 0.481 0.000	A G FOXF2;FOXCUT 0.49 0.481 0.000	Intergenic A G FOXF2,FOXCUT 0.49 0.481 0.000	1548369 Intergenic A G FOXF2;FOXCUT 0.49 0.481 0.000	chr6 1548369 Intergenic A G FOXF2;FOXCUT 0.49 0.481 0.000
0.000	0.695 0.000	0.68 0.695 0.000	AFAP1 0.68 0.695 0.000	G AFAP1 0.68 0.695 0.000	A G AFAP1 0.68 0.695 0.000	Intronic A G AFAP1 0.68 0.695 0.000	7896213 Intronic A G AFAP1 0.68 0.695 0.000	chr4 7896213 Intronic A G AFAP1 0.68 0.695 0.000
0.000	0.329 0.000	0.29 0.329 0.000	AFAP1 0.29 0.329 0.000	T AFAP1 0.29 0.329 0.000	C T AFAP1 0.29 0.329 0.000	Intronic C T AFAP1 0.29 0.329 0.000	7846240 Intronic C T AFAP1 0.29 0.329 0.000	chr4 7846240 Intronic C T AFAP1 0.29 0.329 0.000
0.000	0.181 0.000	0.18 0.181 0.000	AFAP1 0.18 0.181 0.000	G AFAP1 0.18 0.181 0.000	A G AFAP1 0.18 0.181 0.000	Intronic A G AFAP1 0.18 0.181 0.000	7891545 Intronic A G AFAP1 0.18 0.181 0.000	chr4 7891545 Intronic A G AFAP1 0.18 0.181 0.000
0.155	0.700 - 0.155	0.76 0.700 - 0.155	LINC00574;LOC102724511 0.76 0.700 – 0.155	G LINC00574;LOC102724511 0.76 0.700 – 0.155	A G LINC00574;LOC102724511 0.76 0.700 – 0.155	Intergenic A G LINC00574;LOC102724511 0.76 0.700 – 0.155	170454915 Intergenic A G LINC00574;LOC102724511 0.76 0.700 – 0.155	chr6 170454915 Intergenic A G LINC00574;LOC102724511 0.76 0.700 – 0.155
0.286	0.419 — 0.286	0.5 0.419 -0.286	LINC00574;LOC102724511 0.5 0.419 - 0.286	A LINC00574;LOC102724511 0.5 0.419 – 0.286	G A LINC00574;LOC102724511 0.5 0.419 – 0.286	Intergenic G A LINC00574;LOC102724511 0.5 0.419 – 0.286	170464367 Intergenic G A LINC00574;LOC102724511 0.5 0.419 – 0.286	chr6 170464367 Intergenic G A LINC00574;LOC102724511 0.5 0.419 – 0.286
0.000	0.319 0.000	0.33 0.319 0.000	ANKH 0.33 0.319 0.000	T ANKH 0.33 0.319 0.000	C T ANKH 0.33 0.319 0.000	Intronic C T ANKH 0.33 0.319 0.000	14820927 Intronic C T ANKH 0.33 0.319 0.000	chr5 14820927 Intronic C T ANKH 0.33 0.319 0.000
0.000	0.919 0.000	0.91 0.919 0.000	SEMA3CLOC105369146 0.91 0.919 0.000	G SEMA3C,LOC105369146 0.91 0.919 0.000	A G SEMA3CLOC105369146 0.91 0.919 0.000	Intergenic A G SEMA3C,LOC105369146 0.91 0.919 0.000	80838977 Intergenic A G SEMA3CLOC105369146 0.91 0.919 0.000	chr7 80838977 Intergenic A G SEMA3C,LOC105369146 0.91 0.919 0.000
0.046	0.167 — 0.046	0.21 0.167 - 0.046	SIX6 0.21 0.167 – 0.046	A SIX6 0.21 0.167 - 0.046	C A SIX6 0.21 0.167 -0.046	Exonic C A SIX6 0.21 0.167 – 0.046	60976537 Exonic C A SIX6 0.21 0.167 – 0.046	chr14 60976537 Exonic C A SIX6 0.21 0.167 – 0.046
0.000	0.271 0.000	0.28 0.271 0.000	PMM2 0.28 0.271 0.000	C PMM2 0.28 0.271 0.000	A C PMM2 0.28 0.271 0.000	Intronic A C PMM2 0.28 0.271 0.000	8896931 Intronic A C PMM2 0.28 0.271 0.000	chr16 8896931 Intronic A C PMM2 0.28 0.271 0.000
0.000	0.443 0.000	0.48 0.443 0.000	BICC1 0.48 0.443 0.000	C BICC1 0.48 0.443 0.000	T C BICC1 0.48 0.443 0.000	Intronic T C BICC1 0.48 0.443 0.000	60338753 Intronic T C BICC1 0.48 0.443 0.000	chr10 60338753 Intronic T C BICC1 0.48 0.443 0.000
0.000 0.0	0.005 0.000 0.0	0.0099 0.005 0.000 0.0	CAV2;CAV1 0.0099 0.005 0.000 0.0	A CAV2;CAV1 0.0099 0.005 0.000 0.0	G A CAV2;CAV1 0.0099 0.005 0.000 0.0	Intergenic G A CAV2;CAV1 0.0099 0.005 0.000 0.0	116162729 Intergenic G A CAV2;CAV1 0.0099 0.005 0.00	chr7 116162729 Intergenic G A CAV2;CAV1 0.0099 0.005 0.00
0.000 0.7	0.805 0.000 0.7	0.8 0.805 0.000 0.7	TFEC;TES 0.8 0.805 0.000 0.7	G TFECTES 0.8 0.805 0.00 0.7	A G TFEC;TES 0.8 0.805 0.00 0.7	Intergenic A G TFEC;TES 0.8 0.805 0.00 0.7	115810676 Intergenic A G TFEC;TES 0.8 0.805 0.00 0.7	chr7 115810676 Intergenic A G TFEC;TES 0.8 0.805 0.07 0.7
	0.471 0.457 0.467 0.467 0.481 0.481 0.481 0.329 0.181 0.319 0.419 0.310 0.319 0.310 0.319 0.3100 0.3100 0.3100 0.3100 0.3100 0.3100 0.3100 0.310000000000	0.49 0.471 0.47 0.457 0.49 0.467 0.49 0.467 0.49 0.467 0.49 0.467 0.49 0.467 0.49 0.467 0.49 0.467 0.29 0.481 0.29 0.329 0.18 0.329 0.18 0.329 0.181 0.319 0.5 0.419 0.33 0.319 0.319 0.319 0.31 0.919 0.21 0.919 0.21 0.0167 0.28 0.271 0.28 0.271 0.443 0.443 0.0059 0.0055	ABCA1;SLC44A1 0.49 0.471 ABCA1;SLC44A1 0.47 0.457 ABCA1;SLC44A1 0.49 0.467 ABCA1;SLC44A1 0.49 0.467 ABCA1;SLC44A1 0.49 0.467 FOXF2;FOXCUT 0.49 0.467 AFAP1 0.181 0.181 AFAP1 0.29 0.329 AFAP1 0.18 0.181 LINC00574;LOC102724511 0.766 0.700 LINC00574;LOC102724511 0.5 0.419 ANKH 0.33 0.319 ANKH 0.33 0.319 SIX6 0.21 0.700 SIX6 0.21 0.167 PMM/2 0.21 0.167 SIX6 0.21 0.167 BICC1 0.48 0.443 CAV2;CAV1 0.0099 0.005 TFEC;TES 0.8 0.805	A ABCA1;SLC44A1 0.49 0.471 A ABCA1;SLC44A1 0.47 0.457 A ABCA1;SLC4AA1 0.47 0.457 A ABCA1;SLC4AA1 0.49 0.467 G FOXF2;FOXCUT 0.49 0.467 G FOXF2;FOXCUT 0.49 0.467 G FOXF2;FOXCUT 0.49 0.481 G FOXF2;FOXCUT 0.49 0.481 G AFAP1 0.29 0.329 G AFAP1 0.29 0.319 G AFAP1 0.29 0.319 A LINC00574;LOC102724511 0.5 0.419 - A LINC00574;LOC102724511 0.5 0.419 - A NKH 0.33 0.319 - A SiX6 0.21 0.21 0.167 - A NRH 0.33 0.319 0.319 - A SiX6 0.21 0.21 0.167	G A ABCA1;SLC44A1 0.49 0.471 G A ABCA1;SLC44A1 0.49 0.477 0.457 G A ABCA1;SLC44A1 0.49 0.467 0.457 G A BBCA1;SLC44A1 0.49 0.467 0.457 A G A ABCA1;SLC44A1 0.49 0.467 A G FOXF2;FOXCUT 0.49 0.461 0.461 A G AFAP1 0.29 0.329 0.532 A G AFAP1 0.29 0.319 - A G AIRAP1 0.56 0.700 - C T AIRAP1 0.56 0.710 - G AFAP1 0.76 0.33 0.319 - A G LINC00574;LOC102724511 0.56 0.710 - C T ANKH 0.33 0.319 - A G SEMA3C;LOC1025369146 0.916<	Intergenic G A ABCA1;SLC44A1 0.49 0.471 Intergenic G A ABCA1;SLC44A1 0.49 0.467 Intergenic G A ABCA1;SLC44A1 0.49 0.467 Intergenic G A ABCA1;SLC44A1 0.49 0.467 Intergenic G ABCA1;SLC44A1 0.49 0.467 Intergenic A G FOXF2;FOXCUT 0.49 0.461 Intronic C T AFAP1 0.29 0.481 Intronic A G AFAP1 0.29 0.329 Intronic A G AFAP1 0.29 0.319 Intergenic A G LINC00574;LOC102724511 0.56 0.7100 Intergenic A G NIH 0.33 0.319 Intergenic A G LINC00574;LOC102724511 0.56 0.710 Intergenic A G NINH 0.33 0.319	107695848 Intergenic G A ABCA1,SLC44A1 0.49 0471 107695353 Intergenic G A ABCA1,SLC44A1 0.49 0.47 107695353 Intergenic G A ABCA1,SLC44A1 0.49 0.467 107703934 Intergenic G A ABCA1,SLC44A1 0.49 0.467 1548369 Intergenic A G ABCA1,SLC44A1 0.49 0.467 1548369 Intergenic A G AFAP1 0.49 0.481 7896213 Intronic C T AFAP1 0.29 0.329 7891545 Intronic A G AFAP1 0.29 0.319 7891545 Intronic A G AFAP1 0.29 0.319 7891545 Intergenic A G LINC00574;LOC102724511 0.700 0.319 170464367 Intergenic A G LINC00574;LOC102724511 0.710 0.319	chr9 107695848 Intergenic G A ABCA1;SLC4A1 0.49 0.471 chr9 107695353 Intergenic G A ABCA1;SLC4A1 0.49 0.471 chr9 107703934 Intergenic G A ABCA1;SLC4A1 0.49 0.467 chr9 107703934 Intergenic G A ABCA1;SLC4A1 0.49 0.467 chr6 1548369 Intergenic G A ABCA1;SLC4A1 0.49 0.467 chr6 1548369 Intergenic A G AEAP1 0.49 0.481 chr4 789513 Intronic A G AFAP1 0.29 0.329 chr6 170454367 Intronic A G AFAP1 0.29 0.318 chr6 170454367 Intergenic A G AFAP1 0.29 0.318 chr6 7891545 Intergenic A G O A AFAP1 0.29 </td

Table 2 (cont	tinued)												
SNP ID	Chr	Position	Type	Ref Allele	Alt Allele	Nearby/containing Gene	Global East Asian EAF	CHS EAF	CHS log ₁₀ P	CDX EAF	CDX log ₁₀ P	KHV EAF	KHV log ₁₀ P
rs5756813	chr22	38175477	Intergenic	J	F	TRIOBP;H1F0	0.71	0.724	0.000	0.849	2.955	0.717	0.000
rs58073046	chr11	120248493	Intronic	A	U	ARHGEF12	0.17	0.167	0.000	0.215	0.447	0.167	0.000
rs61394862	chr5	14851094	Intronic	U	⊢	ANKH	0.32	0.319	0.000	0.323	0.000	0.298	- 0.041
rs6478746	chr9	129367398	Intergenic	IJ	A	MVB12B;LMX1B	0.97	0.976	0.000	0.946	- 0.945	0.944	- 0.944
rs66602224	chr8	108293718	Intronic	ט	A	ANGPT1	0.14	0.167	0.000	0.075	— 0.945	0.131	0.000
rs6732795	chr2	69411517	Intronic	A	U	ANTXR1	0.85	0.819	0.000	0.823	- 0.175	0.869	0.040
rs73174345	chr3	169252883	Intronic	T	IJ	MECOM	0	0.000	0.000	0000	0.000	0.000	0.000
rs746491	chr11	86406159	Intergenic	U	A	ME3;PRSS23	0.14	0.129	0.000	0.086	- 0.715	0.096	- 0.170
rs7518099	chr1	165736880	Intronic	U	L	TMC01	0.99	0.976	— 0.046	1.000	0.175	066.0	0.000
rs7555523	chr1	165718979	Intronic	U	A	TMC01	0.99	0.976	— 0.046	1.000	0.175	066.0	0.000
rs7924522	chr11	128380742	Intronic	U	A	ETS1	0.86	0.876	0.000	0.742	- 2.617	0.859	0.000
rs8141433	chr22	19854006	Intergenic	A	IJ	GNB1L;TXNRD2	0.037	0.033	0.000	0.022	- 0.175	0.020	- 0.079
rs9284802	chr3	85095766	Intronic	U	A	CADM2	0.17	0.152	0.000	0.134	- 0.215	0.172	0.000
rs945686	chr9	129378026	Intronic	U	U	LMX1B	0.99	0.995	0.000	0.989	0.000	0.980	- 0.079
rs9494457	chr6	136474794	Intronic	L	A	PDE78	0.33	0.262	— 0.381	0.328	0.000	0.439	2.084
rs9853115	chr3	186131600	Intergenic	Т	A	DGKG;LINC02052	0.73	0.752	0.000	0.753	0.169	0.753	0.079
rs9913911	chr17	10031183	Intronic	A	0	GAS7	0.5	0.519	0.000	0.522	0.175	0.414	- 2.084
SNP ID	Chr	Position	Type	Ref Al	lele Alt /	Allele Nearby/containing	Gene CHI	B EAF CI	HB log ₁₀ P	PT EAF J	PT log ₁₀ P	(OR EAF	KOR log ₁₀ P
rs1013278	chr7	117603820	Intergenic	5	U	CTTNBP2;LSM8	0.12	26	0.216 0		- 0.081	0.114	0.413
rs10281637	chr7	116151338	Intergenic	L .	U	CAV2;CAV1	.0.0	15	0.133 0	- 000:	- 0.232 (0.007	- 0.169
rs10483727	chr14	61072875	Intergenic	L 	U	SIX6;SALRNA1	0.3	16	4.865 0	1.260 1	.092 (0.271	3.218
rs10505100	chr8	108278616	Intronic	U	A	ANGPT1	0.27	72	0.285 0	.303 C	.819 (0.283	2.435
rs10918274	chr1	165714416	Intronic	⊢	U	TMC01	0.9	95	0.059 0	.995 C	047 (.993	0.229
rs11217878	chr11	120340383	Intronic	U	A	ARHGEF12	0.15	- 68	- 0.328 0		- 0.023 (0.227	- 0.229
rs113985657	chr6	597203	Intronic	U	⊢	EXOC2	0.18	39	0.430 0	.144 C	.004 (0.208	4.434
rs11710139	chr3	150059342	Intergenic	5	A	LINC01214;TSC22D;	2 0.05	76	0.195 0	.120 0	.779 ()	0.096	0.939
rs12377624	chr9	129373110	Intergenic	5	U	MVB12B;LMX1B	0.1	46	0.078 0	.125 –	- 0.004 (0.079	- 4.387
rs1254276	chr14	60847001	Intergenic	U	⊢	LINC02322;C14orf3!	9.0.68	- 68	- 1.099 0	.745 -	- 0.295 (0.727	- 2.493
rs12699251	chr7	11679113	Intronic	Þ	U	THSD7A	0.18	7	- 0.059 0	.207 0	.023 ().229	0.876
rs1579050	chr2	153364527	Intronic	Þ	U	FMNL2	20.0	29	0.038		- 0.343 (0.025	- 0.017
rs17752199	chr6	51406848	Intergenic	A	U	TFAP2B;PKHD1	0.1		- 0.059 0	.115 -	- 0.023 (0.103	— 0.624
rs1874458	chr16	65080739	Intronic	U	A	CDH11	0.27	28	0.078 0	.212 0	000).250	1.588
rs2022945	chr8	108251139	Intergenic	A	J	ABRA;ANGPT1	0.75	33	- 0.195 0	.702 -	- 0.779 (.723	- 2.027

(pa	
inue	
cont	
ั ร	

Table 2 (cont	tinued)											
SNP ID	Chr	Position	Type	Ref Allele	Alt Allele	Nearby/containing Gene	CHB EAF	CHB log ₁₀ P	JPT EAF	JPT log ₁₀ P	KOR EAF	KOR log ₁₀ P
rs2024211	chr7	116153025	Intergenic	A	υ	CAV2;CAV1	0.015	0.133	0.000	- 0.232	0.007	- 0.169
rs2073006	chr6	637465	Intronic	U	Τ	EXOC2	0.189	0.430	0.183	0.440	0.220	4.434
rs2188836	chr7	117635382	Intergenic	U	μ	CTTNBP2;LSM8	0.107	0.133	0.091	0.000	0.095	0.098
rs2317961	chr6	1533116	Intergenic	A	U	FOXF2;FOXCUT	0.549	0.195	0.466	- 0.313	0.475	— 0.904
rs2472493	chr9	107695848	Intergenic	U	A	ABCA1;SLC44A1	0.519	0.285	0.447	- 0.685	0.460	— 0.711
rs2472496	chr9	107695353	Intergenic	U	A	ABCA1;SLC44A1	0.485	0.059	0.438	- 0.203	0.428	- 1.306
rs2487032	chr9	107703934	Intergenic	U	A	ABCA1;SLC44A1	0.510	0.059	0.505	0.047	0.476	- 0.209
rs2745572	chr6	1548369	Intergenic	A	U	FOXF2;FOXCUT	0.451	- 0.430	0.519	0.346	0.517	0.624
rs28500712	chr4	7896213	Intronic	A	U	AFAP1	0.752	0.489	0.649	— 0.191	0.709	0.767
rs28520091	chr4	7846240	Intronic	U	Γ	AFAP1	0.214	- 0.598	0.279	- 0.025	0.295	0.076
rs28795989	chr4	7891545	Intronic	A	U	AFAP1	0.184	0.035	0.188	0.035	0.170	- 0.196
rs2935057	chr6	1 7045491 5	Intergenic	A	U	LINC00574;LOC102724511	0.733	- 0.133	0.793	0.236	0.729	- 0.913
rs3013274	chr6	170464367	Intergenic	U	A	LINC00574;LOC102724511	0.379	— 1.458	0.587	0.867	0.428	- 3.235
rs31918	chr5	14820927	Intronic	U	T	ANKH	0.316	- 0.051	0.375	0.339	0.334	0.054
rs327716	chr7	80838977	Intergenic	A	U	SEMA3C;LOC105369146	0.942	0.285	0.904	- 0.025	0.947	3.495
rs33912345	chr14	60976537	Exonic	U	A	SIX6	0.311	1.376	0.255	0.351	0.268	2.976
rs3785176	chr16	8896931	Intronic	A	U	PMM2	0.267	- 0.052	0.322	0.329	0.316	1.128
rs4141671	chr10	60338753	Intronic	L	U	BICC1	0.519	0.195	0.529	0.339	0.489	0.113
rs4236601	chr7	116162729	Intergenic	0	A	CAV2;CAV1	0.015	0.133	0.000	- 0.779	0.007	- 0.229
rs55892100	chr7	115810676	Intergenic	A	U	TFEC;TES	0.772	- 0.133	0.841	0.346	0.835	1.552
rs5756813	chr22	38175477	Intergenic	U	T	TRIOBP;H1F0	0.728	0.059	0.529	- 4.121	0.643	— 3.218
rs58073046	chr11	120248493	Intronic	A	U	ARHGEF12	0.155	- 0.059	0.159	- 0.035	0.168	- 0.023
rs61394862	chr5	14851094	Intronic	U	Т	ANKH	0.301	- 0.059	0.365	0.339	0.333	0.196
rs6478746	chr9	129367398	Intergenic	U	A	MVB12B;LMX1B	0.971	0.000	0.990	1.200	0.967	- 0.106
rs66602224	chr8	108293718	Intronic	U	A	ANGPT1	0.189	0.430	0.144	0.004	0.204	4.208
rs6732795	chr2	69411517	Intronic	A	U	ANTXR1	0.825	- 0.133	0.894	0.489	0.900	3.633
rs73174345	chr3	169252883	Intronic	L	0	MECOM	0.000	0.000	0.000	0.000	0.000	0.000
rs746491	chr11	86406159	Intergenic	U	A	ME3;PRSS23	0.180	0.285	0.221	1.329	0.193	3.194
rs7518099	chr1	165736880	Intronic	U	F	TMC01	0.995	0.059	0.995	0.047	0.993	0.229
rs7555523	chr1	165718979	Intronic	U	A	TMC01	0.995	0.059	0.995	0.047	0.993	0.229
rs7924522	chr11	128380742	Intronic	U	A	ETS1	0.859	0.000	0.933	1.329	0.907	3.495
rs8141433	chr22	19854006	Intergenic	A	IJ	GNB1L;TXNRD2	0.029	- 0.059	0.077	1.092	0.040	0.113
rs9284802	chr3	85095766	Intronic	U	A	CADM2	0.150	- 0.099	0.255	1.296	0.176	0.106
rs945686	chr9	129378026	Intronic	J	U	LMX1B	066.0	0:000	1.000	0.339	0.987	- 0.169

(continued)	
2	
Ð	
Q	
Ta	

SNP ID	Chr	Position	Type	Ref Allele	Alt Allele	Nearby/containing Gene	CHB EAF	CHB log ₁₀ P	JPT EAF	JPT log ₁₀ P	KOR EAF	KOR log ₁₀ P
rs9494457	chr6	136474794	Intronic	н	A	PDE7B	0.340	0.051	0.284	- 0.530	0.282	- 1.983
rs9853115	chr3	186131600	Intergenic	T	A	DGKG;LINC02052	0.757	0.195	0.654	— 1.329	0.701	- 0.768
rs9913911	chr17	10031183	Intronic	A	U	GAS7	0.466	- 0.285	0.572	1.376	0.554	2.055
		t allala fuero ano a	and a labor of a labor of a labor	le the plane of the second	Inter attended	in the second		ince Deite Vish.	D annual and	ni dai M M M Maria		in . Matazar

Chr. chromosome, EAF: effect allele frequency, ref allele: reference allele, alt allele: alterative allele, CHS: Southern Han Chinese, China, CDX: Chinese Dai in Xishuangbanna, China, KHV: Kinh in Ho Chi Minh City, Vietnam, CHB: Han Chinese in Beijing, China, PF: Japanese in Tokyo in 1000 genome project, KOR: Korean Reference Genome data base, *P*-value: adjusted Fischer's test, statistical significance was set at *P*<0.05 and |log₁₀ P|>1.301



relationships of genetic loci with OAG or IOP elevation in OAG [25, 32, 33]. Although there is a Genome Aggregation Database (gnomAD) with more numbers, the authors thought that 1000 Genomes Projects would fit the design of this study, which being representative genome data and well-designed public data of wholegenome sequencing data from various populations around the world. Also, data of 1000 Genomes Projects was used for the gene target prediction model in the previous large POAG/IOP study [25]. Combining the results of these studies and the Korean whole-genome data, our study had identified the differences in allele frequencies of SNPs related to OAG or IOP elevation in OAG for worldwide populations as well as the relationship between the composite genetic risk scores and the prevalence in OAG or OAG with high IOP according to populations of diverse ancestry. The present study highlighted that the genetic risk of OAG with high IOP was present in Europeans, Americans, South Asians, Africans, and East Asians, in that order and showed a positive correlation with actual prevalence.

Our findings demonstrated that the prevalence of OAG differed among populations of diverse ancestry and was positively correlated with genetic factors. These results

are consistent with those of the previous study by Kapetanakis et al., which demonstrated the global variations and time trends in the prevalence of OAG [14]. In their study, among people over 80 years of age, Latinos (AMR) had the highest OAG prevalence, followed by blacks (AFR), whites (EUR), South Asians, and East Asians, and this distribution was consistent with our genetic risk score results. For people with an age of 40 years, the population prevalence of OAG was highest in Africans (4.5%), followed by Americans (3.5%), Europeans (2.1%), South Asians (2.0%), and East Asians (1.8%).

The advantage of our study is that we used the data of IOP-related SNPs in OAG, derived from a study using GERA cohort [32], a large multi-ethnic study for identifying novel loci related to IOP [33], and meta-analysis results of IGGC, ANZRAG, and UKBB [23–26]. Although NTG is considered as a type of OAG with an IOP \leq 21 mmHg, controversy exists regarding whether NTG should be regarded as a disease within the spectrum of OAG or a distinctive disease. The focus of this study was not on the pathogenesis of NTG but on the SNPs known to be related to IOP in OAG and the prevalence of OAG with high IOP. In countries other than Asia, there are limited data on NTG proportion [12], but our study showed that the IOP-dependent



Asian population. The heatmap shows how significantly the effect alleles are enriched or depleted in each population. Each row shows SNPs, and each column shows populations of diverse ancestry. Red color means effect allele is enriched, whereas purple color means effect allele is depleted ($\log_{10} P > 1.301$ indicated enrichment, $\log_{10} P < -1.301$ indicated depletion). A hierarchical clustering tree shows the differences among East Asians, KOR, JPT, and CHB in one cluster, and CHS, and CDX in another cluster. CDX: Chinese Dai in Xishuangbanna, CHB: Han Chinese in Beijing, China, CHS: Southern Han Chinese, China, JPT: Japanese in Tokyo, Japan, KOR: Korean in Republic Korea, KHV: Kinh in Ho Chi Minh City, Vietnam



Fig. 4 Correlation plots of the prevalence of open-angle glaucoma and genetic risk score using related single nucleotide polymorphisms. **a** The genetic risk score of OAG according to populations of different ancestry was highest in Africans, followed by Europeans, South Asians, and East Asians. **b** The prevalence of OAG was correlated with the population average genetic risk score (R = 0.293). AMR: American, EUR: Europeans, SAS: South Asians, AFR: Africans, EAS: East Asians. ACB: African Caribbean in Barbados, ASW: African Ancestry in Southwest US, BEB: Bengali in Bangladesh, CDX: Chinese Dai in Xishuangbanna, CEU: Utah residents with Northern and Western European ancestry, CHB: Han Chinese in Beijing, China, CHS: Southern Han Chinese, China, CLM: Colombian in Medellin, Colombia, ESN: Esan in Nigeria, FIN: Finnish in Finland, GBR: British in England and Scotland, GIH: Gujarati Indian in Houston, TX, GWD: Gambian in Western Division, The Gambia, IBS: Iberian populations in Spain, ITU: Indian Telugu in the UK, JPT: Japanese in Tokyo, Japan, KOR: Korean in Republic Korea, KHV: Kinh in Ho Chi Minh City, Vietnam, LWK: Luhya in Webuye, Kenya, MSL: Mende in Sierra Leone, MXL: Mexican Ancestry in Los Angeles, California, PEL: Peruvian in Lima, Peru, PJL: Punjabi in Lahore, Pakistan, PUR: Puerto Rico, STU: Sri Lankan Tamil in the UK, TSI: Toscani in Italy, YRI: Yoruba in Ibadan, Nigeria



Ancestry in Los Angeles, California, PEL: Peruvian in Lima, Peru, PJL: Punjabi in Lahore, Pakistan, PUR: Puerto Rican in Puerto Rico, STU: Sri Lankan Tamil in the UK, TSI: Toscani in Italy, YRI: Yoruba in Ibadan, Nigeria

mechanism in OAG could be explained according to populations of diverse ancestry. On the aspect of allele frequency, the IOP-dependent mechanism was highest in Europeans, followed by South Asians, Americans, Africans, and finally, East Asians. These results suggested that the IOP-dependent mechanism was less prominent in Koreans and Japanese.

Our results suggested that IOP-related SNPs for African ancestry might have been less enrolled, as SNPs were different because most of SNPs were derived from Europeans studies. A recent study on the association of genetic variants with OAG with individuals with African ancestry reported that rs59892895T > C risk allele was the appreciable frequency in Africans, but not in Europeans or Asians [38]. As these alleles were not included in our study, then other results would be expected, considering the prevalence of OAG in African ancestry. In addition, further studies on glaucoma cohorts of Asians and Americans are necessary to identify the differences in genetic variants with respect to those associated with African ancestry.

A recent study on multi-trait analysis of glaucoma used polygenic prediction for glaucoma progression in early manifest glaucoma cases and surgical intervention in advanced glaucoma cases, which could facilitate the development of a personalized approach for treatment [39]. In addition, another study showed that the association of polygenic risk score with IOP improved the prediction of OAG [40]. Our findings also showed a trend in genetic risk and glaucoma prevalence. These results demonstrated the importance of IOP as well as genetic factors in glaucoma development and progression. The particular contributions of the genes to the pathogenesis of OAG, however, remain to be elucidated. Moreover, the major heritable component of OAG is still unexplained. Further studies are necessary for glaucoma specialists to discover genetic variants to explain the identified associations and investigate any gene–gene or gene-environment interactions.

This study may insight the prevalence difference of OAG and NTG according to region and country. In European descent, most glaucoma is known to be POAG with high IOP, and POAG with normal IOP is known to be the minority. However, in East Asians, especially in Japan and Korea, most of the OAG is NTG. Since glaucoma treatment is a management of lowering IOP and other risk factors, understanding the genetic difference in SNP frequencies with IOP would provide sufficient insights regarding the pathogenesis of glaucoma for clinical ophthalmologists and glaucoma specialists. A major strength

of our study was the inclusion of the large Korean wholegenome data (n = 1722) to reflect the allele frequency of SNPs related to OAG and OAG with high IOP. Additionally, we did not systematically organize the new glaucoma cohort and analyze the effects; instead, we compared the 1000 Genomes Project data with OAG-related SNP data from the GWAS catalog. However, there are a few limitations to this study. First, the GWAS catalog contains data for which the risk allele is not clearly defined in the minor allele frequency (MAF). However, we did not exclude these in our study because the majority of MAFs are likely to be risk alleles, so removing all of the undefined alleles would result in inaccurate subgroup analysis. Further study is needed for the data curation of 32 undefined SNPs. To solve this problem, risk allele curation is necessary for the GWAS catalog, based on further results of large population studies using glaucoma cohorts. Second, the statistical significance of EAF in Koreans was high and should be interpreted with caution since the Fisher's test can decrease the *P*-value as the number of subjects increases, even with the same odds ratio values as the Korean reference genome number was 1722, which was very high, assuming that the genome number of 26 populations belonging to the 1000 Genomes Project was about 100, ranging from 61 to 113. Third, we used the composite risk score that did not include the effect size weights, as the weighted-odd ratios vary according to the ethnic group even for the same SNP, and there are inaccuracies due to insufficient study data on OAG-related SNPs in the Africans and Asians population. In the future, the polygenic risk score with the effect size weighted odd ratio will be a more desirable study. Fourth, our study analyzed what is currently known; it is not a study that shows new genetic loci or pathway analysis using cell culture and animal study. Additionally, our findings should be interpreted in consideration of the fact that the penetrance is variable even when causative SNPs are present in specific individuals. Nevertheless, it would be meaningful to understand genetic research from the point of view of a clinical glaucoma specialist.

Conclusions

Our study showed substantial population differentiation in allele frequencies in both of OAG-related SNPs and IOP-related SNPs in OAG. From the allele frequency of these SNPs, we calculated the composite risk scores for OAG and OAG with high IOP for 26 ethnic groups in the 1000 Genomes Project and Koreans. In addition, the prevalence of OAG and OAG with high IOP correlated with genetic risk scores. We observed differences in allele frequencies associated with SNPs related to IOP in OAG between Koreans and other populations of diverse ancestry, which may explain the high prevalence of OAG with normal IOP predominantly in Koreans and East Asians.

Abbreviations

AFR: African; AMR: American; ANZRAG: Australian and New Zealand Registry of Advanced Glaucoma; EAFs: Effect allele frequencies; EAS: East Asian; EUR: European; GWAS: Genome-wide association studies; IGGC: International Glaucoma Genetics Consortium; IOP: Intraocular pressure; ISGEO: International Society of Geographical and Epidemiological Ophthalmology; KOR: Korean; KRGDB: Korean Reference Genome Database; MAF: Minor allele frequency; NTG: Normal-tension glaucoma; OAG: Open-angle glaucoma; SAS: South Asian; SNP: Single nucleotide polymorphism; UKBB: UK Biobank.

Supplementary information

The online version contains supplementary material available at https://doi. org/10.1186/s12920-021-00921-2.

Additional file 1. Figure S1. A heatmap generated using open-angle glaucoma-related single nucleotide polymorphisms in the global population and the East Asian population. Figure S2. A Heatmap generated using open-angle glaucoma-related single nucleotide polymorphisms in the East Asian population

Additional file 2. Table S1. Effect allele frequencies (EAFs) of open-angle glaucoma related single nucleotide polymorphisms in populations of diverse ancestry including Koreans.

Additional file 3. Table S2. Effect allele frequencies (EAFs) of open-angle glaucoma-related single nucleotide polymorphisms in East Asian groups, including Koreans.

Acknowledgements

This study was conducted with bio resources from the National Biobank of Korea, the Center for Disease Control and Prevention, Republic of Korea (KBN-2019-053).

Authors' contributions

HTS, and JHS participated in the study concept and design. HTS, BWY, and JHS contributed to acquisition, analysis, or interpretation of data. HTS carried out statistical analysis, administrative, technical, or material support. HTS, BWY, and JHS wrote and revise the manuscript. HTS and JHS did study supervision. All authors read and approved the final manuscript.

Funding

This study was supported by a Veterans Health Service Medical Center Research Grant (grant number: VHSMC19022). The sponsor or funding organization had no role in the design or conduct of this research.

Availability of data and materials

The raw datasets generated and analyzed during the current study are not publicly available since any data providing the whole-genome sequencing data is considered to be personal property by the Korea Bioethics law. However, the raw whole-genome sequencing data for research are available at the reasonable request under the permission of the National Biobank of Korea contact at [http://nih.go.kr/biobank/cmm/main/mainPage.do?/] and e-mail [biobank@korea.kr]. The allele frequency of Korea reference genome data base (KRGDB) is available [http://152.99.75.168:9090/KRGDBDN/dnKRGinput.jsp], files required are all three of 'the totally merged sets' of common variants, rare variants, and indels. The 1000genomes data is available, all the files from the following folder were downloaded, [ftp://ftp.1000genomes.ebi.ac.uk/vol1/ ftp/release/20130502/] (last accessed: January 15, 2020). The genome-wide association study (GWAS) catalog data is available in the (NHGRI-EBI, [https ://www.ebi.ac.uk/gwas/docs/file-downloads], "All associations v1.0.2—with added ontology annotations, GWAS Catalog study accession numbers and genotyping technology", December 2019).

Declarations

Ethics approval and consent to participate

This study was approved and monitored by the Institutional Review Board (IRB) of the Veterans Health Service Medical Center, Korea (IRB No. 2019-07-008) and was conducted in accordance with the Declaration of Helsinki. HTS approved administrative permission after the committee review of the National Biobank of Korea (KBN-2019-053) to access the raw data of Korea Reference Genome Data Base under Korea Bioethics law.Informed consent for this study was waived by the Institutional Review Board (IRB) of the Veterans Health Service Medical Center, Korea (IRB No. 2019-07-008), because the National Biobank of Korea had obtained informed consent to participate for general research and de-identified data granted by National Biobank of Korea by Korea Bioethics law.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹ Veterans Health Service Medical Center, Veterans Medical Research Institute, Jinhwangdo-ro 61-gil 53,Gangdong-gu, Seoul 05368, Korea. ² Department of Dermatology, Inha University School of Medicine, Inha-ro 100, Michuhol-gu, Incheon 22212, Korea. ³ Division of Oncology, Department of Internal Medicine, Inje University Seoul Paik Hospital, Mareunnae-ro 9,Jung-gu, Seoul 04551, Korea.

Received: 21 December 2020 Accepted: 25 February 2021 Published online: 16 March 2021

References

- Quigley HA. Glaucoma Lancet. 2011;377:1367–77. https://doi. org/10.1016/S0140-6736(10)61423-7.
- Tielsch JM, Sommer A, Katz J, Royall RM, Quigley HA, Javitt J. Racial variations in the prevalence of primary open-angle glaucoma. Baltimore Eye Survey JAMA. 1991;266:369–74.
- Klein BE, Klein R, Sponsel WE, Franke T, Cantor LB, Martone J, Menage MJ. Prevalence of glaucoma. The Beaver Dam Eye Study Ophthalmology. 1992;99:1499–504. https://doi.org/10.1016/s0161-6420(92)31774-9.
- Wensor MD, McCarty CA, Stanislavsky YL, Livingston PM, Taylor HR. The prevalence of glaucoma in the Melbourne Visual Impairment Project. Ophthalmology. 1998;105:733–9. https://doi.org/10.1016/S0161 -6420(98)94031-3.
- Bonomi L, Marchini G, Marraffa M, Bernardi P, De Franco I, Perfetti S, Varotto A. Epidemiology of angle-closure glaucoma: prevalence, clinical types, and association with peripheral anterior chamber depth in the Egna-Neumarket Glaucoma Study. Ophthalmology. 2000;107:998–1003. https://doi.org/10.1016/s0161-6420(00)00022-1.
- Quigley HA, West SK, Rodriguez J, Munoz B, Klein R, Snyder R. The prevalence of glaucoma in a population-based study of Hispanic subjects: Proyecto VER. Arch Ophthalmol. 2001;119:1819–26. https://doi. org/10.1001/archopht.119.12.1819.
- Day AC, Baio G, Gazzard G, Bunce C, Azuara-Blanco A, Munoz B, Friedman DS, Foster PJ. The prevalence of primary angle closure glaucoma in European derived populations: a systematic review. Br J Ophthalmol. 2012;96:1162–7. https://doi.org/10.1136/bjophthalmol-2011-301189.
- Foster PJ, Oen FT, Machin D, Ng TP, Devereux JG, Johnson GJ, Khaw PT, Seah SK. The prevalence of glaucoma in Chinese residents of Singapore: a cross-sectional population survey of the Tanjong Pagar district. Arch Ophthalmol. 2000;118:1105–11. https://doi.org/10.1001/archopht.118.8.1105.
- Stein JD, Kim DS, Niziol LM, Talwar N, Nan B, Musch DC, Richards JE. Differences in rates of glaucoma among Asian Americans and other racial groups, and among various Asian ethnic groups. Ophthalmology. 2011;118:1031–7. https://doi.org/10.1016/j.ophtha.2010.10.024.
- 10. Mwanza JC, Tulenko SE, Barton K, Herndon LW, Mathenge E, Hall A, Kim HY, Hay-Smith G, Budenz DL. Eight-year incidence of open-angle

glaucoma in the tema eye survey. Ophthalmology. 2019;126:372-80. https://doi.org/10.1016/j.ophtha.2018.10.016.

- Budenz DL, Barton K, Whiteside-de Vos J, Schiffman J, Bandi J, Nolan W, Herndon L, Kim H, Hay-Smith G, Tielsch JM, Tema Eye Survey Study G. Prevalence of glaucoma in an urban West African population: the Tema Eye Survey. JAMA Ophthalmol. 2013;131:651–8. https://doi.org/10.1001/ jamaophthalmol.2013.1686.
- Kim KE, Park KH. Update on the prevalence, etiology, diagnosis, and monitoring of normal-tension glaucoma. Asia Pac J Ophthalmol (Phila). 2016;5:23–31. https://doi.org/10.1097/APO.000000000000177.
- Rudnicka AR, Mt-Isa S, Owen CG, Cook DG, Ashby D. Variations in primary open-angle glaucoma prevalence by age, gender, and race: a Bayesian meta-analysis. Invest Ophthalmol Vis Sci. 2006;47:4254–61. https://doi. org/10.1167/iovs.06-0299.
- Kapetanakis VV, Chan MP, Foster PJ, Cook DG, Owen CG, Rudnicka AR. Global variations and time trends in the prevalence of primary open angle glaucoma (POAG): a systematic review and meta-analysis. Br J Ophthalmol. 2016;100:86–93. https://doi.org/10.1136/bjophthalmol-2015-307223.
- Yamamoto S, Sawaguchi S, Iwase A, Yamamoto T, Abe H, Tomita G, Tomidokoro A, Araie M. Primary open-angle glaucoma in a population associated with high prevalence of primary angle-closure glaucoma: the Kumejima Study. Ophthalmology. 2014;121:1558–65. https://doi. org/10.1016/j.ophtha.2014.03.003.
- Iwase A, Suzuki Y, Araie M, Yamamoto T, Abe H, Shirato S, Kuwayama Y, Mishima HK, Shimizu H, Tomita G, Inoue Y, Kitazawa Y, Tajimi Study Group JGS. The prevalence of primary open-angle glaucoma in Japanese: the Tajimi Study. Ophthalmology. 2004;111:1641–8. https://doi.org/10.1016/j. ophtha.2004.03.029.
- 17. Song W, Shan L, Cheng F, Fan P, Zhang L, Qu W, Zhang Q, Yuan H. Prevalence of glaucoma in a rural northern china adult population: a population-based survey in kailu county, inner mongolia. Ophthalmology. 2011;118:1982–8. https://doi.org/10.1016/j.ophtha.2011.02.050.
- Kim CS, Seong GJ, Lee NH, Song KC, Namil Study Group KGS. Prevalence of primary open-angle glaucoma in central South Korea the Namil study. Ophthalmology. 2011;118:1024–30. https://doi.org/10.1016/j.ophth a.2010.10.016.
- Sommer A, Tielsch JM, Katz J, Quigley HA, Gottsch JD, Javitt JC, Martone JF, Royall RM, Witt KA, Ezrine S. Racial differences in the cause-specific prevalence of blindness in east Baltimore. N Engl J Med. 1991;325:1412–7. https://doi.org/10.1056/NEJM199111143252004.
- Rotchford AP, Johnson GJ. Glaucoma in Zulus: a population-based cross-sectional survey in a rural district in South Africa. Arch Ophthalmol. 2002;120:471–8. https://doi.org/10.1001/archopht.120.4.471.
- Wang X, Harmon J, Zabrieskie N, Chen Y, Grob S, Williams B, Lee C, Kasuga D, Shaw PX, Buehler J, Wang N, Zhang K. Using the Utah Population Database to assess familial risk of primary open angle glaucoma. Vision Res. 2010;50:2391–5. https://doi.org/10.1016/j.visres.2010.09.018.
- Sung VC, Koppens JM, Vernon SA, Pawson P, Rubinstein M, King AJ, Tattersall CL. Longitudinal glaucoma screening for siblings of patients with primary open angle glaucoma: the Nottingham Family Glaucoma Screening Study. Br J Ophthalmol. 2006;90:59–63. https://doi.org/10.1136/ bjo.2005.072751.
- 23. Ozel AB, Moroi SE, Reed DM, Nika M, Schmidt CM, Akbari S, Scott K, Rozsa F, Pawar H, Musch DC, Lichter PR, Gaasterland D, Branham K, Gilbert J, Garnai SJ, Chen W, Othman M, Heckenlively J, Swaroop A, Abecasis G, Friedman DS, Zack D, Ashley-Koch A, Ulmer M, Kang JH, Consortium N, Liu Y, Yaspan BL, Haines J, Allingham RR, Hauser MA, Pasquale L, Wiggs J, Richards JE, Li JZ. Genome-wide association study and meta-analysis of intraocular pressure. Hum Genet. 2014;133:41–57. https://doi.org/10.1007/s00439-013-1349-5.
- 24. Wiggs JL, Hauser MA, Abdrabou W, Allingham RR, Budenz DL, Delbono E, Friedman DS, Kang JH, Gaasterland D, Gaasterland T, Lee RK, Lichter PR, Loomis S, Liu Y, McCarty C, Medeiros FA, Moroi SE, Olson LM, Realini A, Richards JE, Rozsa FW, Schuman JS, Singh K, Stein JD, Vollrath D, Weinreb RN, Wollstein G, Yaspan BL, Yoneyama S, Zack D, Zhang K, Pericak-Vance M, Pasquale LR, Haines JL. The NEIGHBOR consortium primary open-angle glaucoma genome-wide association study: rationale, study design, and clinical variables. J Glaucoma. 2013;22:517–25. https://doi. org/10.1097/IJG.0b013e31824d4fd8.

- MacGregor S, Ong JS, An J, Han X, Zhou T, Siggs OM, Law MH, Souzeau E, Sharma S, Lynn DJ, Beesley J, Sheldrick B, Mills RA, Landers J, Ruddle JB, Graham SL, Healey PR, White AJR, Casson RJ, Best S, Grigg JR, Goldberg I, Powell JE, Whiteman DC, Radford-Smith GL, Martin NG, Montgomery GW, Burdon KP, Mackey DA, Gharahkhani P, Craig JE, Hewitt AW. Genomewide association study of intraocular pressure uncovers new pathways to glaucoma. Nat Genet. 2018;50:1067–71. https://doi.org/10.1038/s4158 8-018-0176-y.
- Gao XR, Huang H, Nannini DR, Fan F, Kim H. Genome-wide association analyses identify new loci influencing intraocular pressure. Hum Mol Genet. 2018;27:2205–13. https://doi.org/10.1093/hmg/ddy111.
- Welter D, MacArthur J, Morales J, Burdett T, Hall P, Junkins H, Klemm A, Flicek P, Manolio T, Hindorff L, Parkinson H. The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. Nucleic Acids Res. 2014;42:D1001-1006. https://doi.org/10.1093/nar/gkt1229.
- Genomes Project C, Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, Marchini JL, McCarthy S, McVean GA, Abecasis GR. A global reference for human genetic variation. Nature. 2015;526:68–74. https://doi.org/10.1038/nature15393.
- Kim J, Weber JA, Jho S, Jang J, Jun J, Cho YS, Kim HM, Kim H, Kim Y, Chung O, Kim CG, Lee H, Kim BC, Han K, Koh I, Chae KS, Lee S, Edwards JS, Bhak J. KoVariome: Korean National Standard Reference Variome database of whole genomes with comprehensive SNV, indel, CNV, and SV analyses. Sci Rep. 2018;8:5677. https://doi.org/10.1038/s41598-018-23837-x.
- Foster PJ, Buhrmann R, Quigley HA, Johnson GJ. The definition and classification of glaucoma in prevalence surveys. Br J Ophthalmol. 2002;86:238–42. https://doi.org/10.1136/bjo.86.2.238.
- Mao L, Fang Y, Campbell M, Southerland WM. Population differentiation in allele frequencies of obesity-associated SNPs. BMC Genomics. 2017;18:861. https://doi.org/10.1186/s12864-017-4262-9.
- Choquet H, Paylakhi S, Kneeland SC, Thai KK, Hoffmann TJ, Yin J, Kvale MN, Banda Y, Tolman NG, Williams PA, Schaefer C, Melles RB, Risch N, John SWM, Nair KS, Jorgenson E. A multiethnic genome-wide association study of primary open-angle glaucoma identifies novel risk loci. Nat Commun. 2018;9:2278. https://doi.org/10.1038/s41467-018-04555-4.
- Choquet H, Thai KK, Yin J, Hoffmann TJ, Kvale MN, Banda Y, Schaefer C, Risch N, Nair KS, Melles R, Jorgenson E. A large multi-ethnic genomewide association study identifies novel genetic loci for intraocular pressure. Nat Commun. 2017;8:2108. https://doi.org/10.1038/s41467-017-01913-6.
- Chen F, Klein AP, Klein BE, Lee KE, Truitt B, Klein R, Iyengar SK, Duggal P. Exome array analysis identifies CAV1/CAV2 as a susceptibility locus for intraocular pressure. Invest Ophthalmol Vis Sci. 2014;56:544–51. https:// doi.org/10.1167/iovs.14-15204.
- 35. Bailey JN, Loomis SJ, Kang JH, Allingham RR, Gharahkhani P, Khor CC, Burdon KP, Aschard H, Chasman DI, Igo RP, Jr., Hysi PG, Glastonbury CA, Ashley-Koch A, Brilliant M, Brown AA, Budenz DL, Buil A, Cheng CY, Choi H, Christen WG, Curhan G, De Vivo I, Fingert JH, Foster PJ, Fuchs C, Gaasterland D, Gaasterland T, Hewitt AW, Hu F, Hunter DJ, Khawaja AP, Lee RK, Li Z, Lichter PR, Mackey DA, McGuffin P, Mitchell P, Moroi SE, Perera SA, Pepper KW, Qi Q, Realini T, Richards JE, Ridker PM, Rimm E, Ritch R, Ritchie M, Schuman JS, Scott WK, Singh K, Sit AJ, Song YE, Tamimi RM, Topouzis F, Viswanathan AC, Verma SS, Vollrath D, Wang JJ, Weisschuh N, Wissinger B, Wollstein G, Wong TY, Yaspan BL, Zack DJ, Zhang K, Study EN, Consortium A, Weinreb RN, Pericak-Vance MA, Small K, Hammond CJ, Aung T, Liu Y,

- 36. Carlson CS, Matise TC, North KE, Haiman CA, Fesinmeyer MD, Buyske S, Schumacher FR, Peters U, Franceschini N, Ritchie MD, Duggan DJ, Spencer KL, Dumitrescu L, Eaton CB, Thomas F, Young A, Carty C, Heiss G, Le Marchand L, Crawford DC, Hindorff LA, Kooperberg CL, Consortium P. Generalization and dilution of association results from European GWAS in populations of non-European ancestry: the PAGE study. PLoS Biol. 2013;11:e1001661. https://doi.org/10.1371/journal.pbio.1001661.
- Abu-Amero K, Kondkar AA, Chalam KV. An updated review on the genetics of primary open angle glaucoma. Int J Mol Sci. 2015;16:28886–911. https://doi.org/10.3390/ijms161226135.
- 38. Genetics of Glaucoma in People of African Descent C, Hauser MA, Allingham RR, Aung T, Van Der Heide CJ, Taylor KD, Rotter JI, Wang SJ, Bonnemaijer PWM, Williams SE, Abdullahi SM, Abu-Amero KK, Anderson MG, Akafo S, Alhassan MB, Asimadu I, Ayyagari R, Bakayoko S, Nyamsi PB, Bowden DW, Bromley WC, Budenz DL, Carmichael TR, Challa P, Chen YI, Chuka-Okosa CM, Cooke Bailey JN, Costa VP, Cruz DA, DuBiner H, Ervin JF, Feldman RM, Flamme-Wiese M, Gaasterland DE, Garnai SJ, Girkin CA, Guirou N, Guo X, Haines JL, Hammond CJ, Herndon L, Hoffmann TJ, Hulette CM, Hydara A, Igo RP, Jr., Jorgenson E, Kabwe J, Kilangalanga NJ, Kizor-Akaraiwe N, Kuchtey RW, Lamari H, Li Z, Liebmann JM, Liu Y, Loos RJF, Melo MB, Moroi SE, Msosa JM, Mullins RF, Nadkarni G, Napo A, Ng MCY, Nunes HF, Obeng-Nyarkoh E, Okeke A, Okeke S, Olaniyi O, Olawoye O, Oliveira MB, Pasquale LR, Perez-Grossmann RA, Pericak-Vance MA, Qin X, Ramsay M, Resnikoff S, Richards JE, Schimiti RB, Sim KS, Sponsel WE, Svidnicki PV, Thiadens A, Uche NJ, van Duijn CM, de Vasconcellos JPC, Wiggs JL, Zangwill LM, Risch N, Milea D, Ashaye A, Klaver CCW, Weinreb RN, Ashley Koch AE, Fingert JH, Khor CC. Association of genetic variants with primary open-angle glaucoma among individuals with African ancestry. JAMA. 2019;322:1682-91. https://doi.org/10.1001/jama.2019.16161.
- 39. Craig JE, Han X, Qassim A, Hassall M, Cooke Bailey JN, Kinzy TG, Khawaja AP, An J, Marshall H, Gharahkhani P, Igo RP Jr, Graham SL, Healey PR, Ong JS, Zhou T, Siggs O, Law MH, Souzeau E, Ridge B, Hysi PG, Burdon KP, Mills RA, Landers J, Ruddle JB, Agar A, Galanopoulos A, White AJR, Willoughby CE, Andrew NH, Best S, Vincent AL, Goldberg I, Radford-Smith G, Martin NG, Montgomery GW, Vitart V, Hoehn R, Wojciechowski R, Jonas JB, Aung T, Pasquale LR, Cree AJ, Sivaprasad S, Vallabh NA, consortium N, Eye UKB, Vision C, Viswanathan AC, Pasutto F, Haines JL, Klaver CCW, van Duijn CM, Casson RJ, Foster PJ, Khaw PT, Hammond CJ, Mackey DA, Mitchell P, Lotery AJ, Wiggs JL, Hewitt AW, MacGregor S, . Multitrait analysis of glaucoma identifies new risk loci and enables polygenic prediction of disease susceptibility and progression. Nat Genet. 2020. https://doi.org/10.1038/s41588-019-0556-y.
- Gao XR, Huang H, Kim H. Polygenic Risk Score Is Associated With Intraocular Pressure and Improves Glaucoma Prediction in the UK Biobank Cohort. Transl Vis Sci Technol. 2019;8:10. https://doi.org/10.1167/ tvst.8.2.10.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.